Viral Diversity, Phylogenetics and Phylodynamics

1 Analysis of intra-patient, full length HIV
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Background {#jve2_1-sec-0001}
==========

HIV Gag polyprotein is central to assembly, budding, and maturation of HIV virions, and there is substantial interest in Gag as a therapeutic target. Previously, maturation inhibitors have been limited by natural polymorphisms in *gag*. A more comprehensive analysis of intra-patient *gag* genetic variation, including linkage analysis is essential to inform novel approaches to therapeutics. As a first step, we developed a new single genome sequencing (SGS) assay to analyze full length HIV *gag* to investigate intra-patient genetic variation, localize regions of variability, and determine linkage patterns.

Methods {#jve2_1-sec-0002}
=======

Antiretroviral naïve individuals with detectable HIV RNA were recruited at NIH and Walter Reed National Military Medical Center and underwent phlebotomy. Plasma derived HIV RNA was subjected to cDNA synthesis and PCR primers were designed to amplify the entire 1.5kb fragment from upstream p17 through p6. SGS (9--21 sequences per patient) were aligned (CLUSTAL W), and subjected to phylogenetic (MEGA) and population genetics (DNASP) analyses.

Results {#jve2_1-sec-0003}
=======

Patients (N=22, median age 30 years, 37% non-white, median baseline CD4=568 cells/μl, median HIV RNA=3.9 log10 copies/ml) were enrolled, and 181 sequences from 13 patients have been analyzed thus far (average: 14 sequences/patient). Full length *gag*sequences were genetically diverse (average pairwise difference range 0.4% to 1.59%, one acute patient excluded). Although diversity was present throughout*gag*, most of the variation was attributed to p6. On the protein level, translated p6 sequences had significantly higher average pairwise difference (APD) compared to translated full length *gag* (1.7-fold p=0.041, Students t-test). Indels were common in p6, including PTAP duplications and contribute additional variability. Polymorphisms were common, (mean 45 segregating sites/patient dataset) but no significant linkage between *gag* polymorphisms was detected (Fisher\'s exact=NS, Bonferroni corrected).

Conclusions {#jve2_1-sec-0004}
===========

Intra-patient *gag* genetic diversity is substantial but overall variability is largely limited to p6. No significant linkage between polymorphic positions was detected, indicating that populations were in linkage equilibrium. Next generation sequencing approaches focusing on specific regions in *gag* will be useful in characterizing intra-patient diversity.

Antibody Diversity and Function

2 Increased interferon-alpha activity may contribute to defects of B cells and antibody production caused by HIV-1 infection
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Background {#jve2_2-sec-0001}
==========

HIV-1 infection causes multiple defects of B cells and antibody production, including increased proportions of 'exhausted' B cells (CD20^+^CD21^lo/−^) and increased serum levels of IgG1 and immunoglobulin free light chains (FLCs), whereas serum IgG2 levels and antibody production are decreased. As defects may persist in patients receiving antiretroviral therapy (ART), it is important to understand their cause so that antibody responses to vaccines, including therapeutic HIV vaccines, might be enhanced in ART-treated patients. We have investigated the role of interferon (IFN)-alpha.

Methods {#jve2_2-sec-0002}
=======

The relationship of plasma levels of CXCL10 (induced by IFN-alpha) and soluble (s) IFNAR2 (modulator of IFN-alpha activity) with proportions of 'exhausted' B cells and serum levels of IgG1, IgG2 and FLCs was examined in ART-naïve (n=19) and ART-treated (n=30) patients with HIV-1 infection using cryopreserved plasma, PBMC and serum. Plasma markers of monocyte activation (sCD14) were also examined for comparison. In addition, the relationship between the frequencies of IgG1 and IgG2 antibody secreting cells (ASCs) specific for pneumococcal polysaccharides (PcPs) 4, 6B, 9V and 14 seven days after vaccination with unconjugated PcPs, and plasma levels of CXCL10 and sIFNAR2 before vaccination, was examined in ART-treated patients (n=28).

Results {#jve2_2-sec-0003}
=======

Proportions of 'exhausted' B cells and serum levels of FLCs and IgG1 all correlated with plasma levels of CXCL10 and sIFNAR2 (r≥0.5, p≤0.03 and r ≥0.6, p≤0.01, respectively) in ART-naïve patients. In contrast, serum IgG2 levels correlated negatively with sIFNAR2 (r=−0.6, p=0.007) and CXCL10 (r=−0.4, p=0.09). In ART-treated patients, IgG2 but not IgG1, ASCs to 3 of 4 PcPs (6B, 9V and 14) after vaccination correlated negatively with plasma levels of sIFNAR2 (r≥−0.43, p≤0.02) but not CXCL10 (which had returned to normal levels). There was no relationship between any of these parameters and sCD14.

Conclusions {#jve2_2-sec-0004}
===========

Increased IFN-alpha activity may contribute to defects of B cells and antibody production in patients with HIV-1 infection, including persistent defects of antibody isotype diversification in patients receiving ART. Generation of optimal antibody responses by vaccines in ART-treated patients may require therapeutic modulation of IFN-alpha activity.

Reverse Transcription and Integration

3 HIV-infected patients with exceptional TCD4+ recovery during effective HAART present a distinct T CD4+ differentiation pattern, higher CD31neg naïve cells and a smaller HIV reservoir
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Background {#jve2_3-sec-0001}
==========

Clinical outcome of HIV infected patients relies on the recovery of CD4+ T cells after HAART. However this immune recovery is variable and difficult to predict. Here we present a cohort of patients with undetectable viral load and a follow up of 48 months of HAART who reached CD4+ T cell counts \>1000 cels/mm^3^ (Hypers) and compare them to those who reached between 350 and 999 CD4+ T cels/mm^3^ (concordants). Their demographic data, immune recovery kinetics, and T CD4+ subsets phenotype as well as their integrated HIV DNA were analyzed.

Methods {#jve2_3-sec-0002}
=======

Retrospective data were obtained from the charts of 447 undetectable patients on their first ARV regimen and a follow up of 48 months at the INCMSZ HIV cohort. For immune phenotype and reservoir analysis, 20 Hypers and 19 Concordants matched by sex, age and T CD4+ nadir were available. The following subsets were analyzed by Flow cytometry on whole blood: naïve T-cells, central memory T-cells, effector memory and terminally differentiated. A two-step quantitative real-time PCR (qPCR) method to detect HIV-1 integrated DNA was used, with a DNA pre-amplification using *Alu* and LTR specific primers. Proviral DNA levels were determined by a second round SYBR Green-based qPCR assay in reference to a standard curve.

Results {#jve2_3-sec-0003}
=======

28 Hypers (6%) and 354 concordants (79%) were identified. Hypers had a higher proportion of CD4+ naïve T-cells (37.6 vs 24.8, p\<0.05), and a low proportion of CD4+ EM T Cells (27.9 vs 39.4, p\<0.05), with similar results found in CD8+ T Cells. Hypers presented a higher percentage of CD4+CD45RA+CD31neg cells. There was no difference in total integrated HIV DNA copies per 10^6^ PBMC (1729 vs 3062, p=0.19), however the DNA/CD4 ratio of Hypers was significantly lower (1.2 vs 2.89, p\<0.05).

Conclusions {#jve2_3-sec-0004}
===========

T cell recovery of Hypers occurs very early suggesting cell redistribution, however on the long term, their T CD4+ level is driven by non-thymic-central-naïve cells that are less likely to be HIV infected, thus diluting HIV reservoir. Understanding better immune recovery after HAART and its impact on viral reservoir could contribute to design more effective therapeutic strategies.

HIV-1 controllers (including post-treatment controllers)

4 Post-treatment control or treated controllers? The impact of ART on time to viral rebound in recent seroconverters
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Background {#jve2_4-sec-0001}
==========

In certain individuals who commence antiretroviral therapy (ART) in primary HIV infection (PHI) stopping treatment is not followed by viral rebound, but rather a period of aviraemia or 'viral remission'. However transient viraemic control may also occur in untreated PHI before the plasma viral load (VL) becomes detectable. Characterising these untreated patients is critical to understanding the additional impact of ART on 'time to rebound' in treatment interruption (TI) studies. We studied patients randomised to initiate immediate or deferred ART at the time of PHI to compare factors impacting time to viraemia.

Methods {#jve2_4-sec-0002}
=======

Participants with PHI in the SPARTAC RCT were randomised to 0, 12 or 48 weeks of ART. We defined 'control' as plasma VL\<400 copies/mL for at least 16 weeks after randomisation if untreated, or from TI if ART was initiated. For treated and untreated controllers we compared Total HIV-1 DNA, HLA Class I alleles, HIV-1-specific CD8 T cell responses, and markers of T cell activation (CD25, CD38, CD69, HLA-DR) and exhaustion (PD-1, Tim-3, Lag-3).

Results {#jve2_4-sec-0003}
=======

35 of 361 (9.7%) trial participants fulfilled the definition of control; 10/128 (7.8%) were untreated, 9/114 (7.9%) received ≤12 weeks ART (mean 11.9 weeks) and 16/119 (13.4%) \>12 weeks of ART (mean 47.7 weeks). At baseline, controllers, both treated and untreated, had lower HIV-1 DNA levels (p\<0.001), lower VLs (p\<0.001) and higher CD4 counts (p=0.002) than non-controllers.

When comparing untreated and treated controllers, those who had received \>12 weeks ART had significantly higher pre-therapy VL than untreated controllers (3.8 vs 2.3 log copies/ml; p=0.003). However, there were no differences with respect to demography, viral subtype, HLA allele frequency, baseline HIV-1-specific T cell immunity (median \[range\]: 1 \[0,9\], 1 \[0,4\] Gag OLP responses for \>12 and 0 weeks ART, respectively), CD4 count, HIV-1 DNA, immune exhaustion or activation marker expression. Importantly, the duration of viral control did not vary between treatment groups (p=0.218).

Conclusions {#jve2_4-sec-0004}
===========

These data shows that some untreated patients during PHI experience prolonged viral control, and suggest that the impact of early ART on post-treatment control may be overestimated if the dynamics of viral rebound in untreated individuals are not considered.

HIV-1 controllers (including post-treatment controllers)

5 Identification of different HIV-controller phenotypes: looking for the right model of functional cure
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Background {#jve2_5-sec-0001}
==========

HIV-controllers are a rare group of patients that maintain HIV viremia at low levels without antiretroviral treatment. However, some HIV-controllers differ in terms of clinical outcomes, CD4 T-cell counts and immune activation. Our aim was to find unbiased and premature markers that enable to discern HIV-controller phenotypes regarding clinical progression (CD4+ T-cell drop).

Methods {#jve2_5-sec-0002}
=======

We have analysed the prevalence of IFNL4 ss469415590 polymorphism and HLA-B haplotypes among 100 HIV-controllers (\<2000 HIV-RNA copies/ml in absence of antiretroviral treatment for at least 1 year) Long Term Non-Progressors (CD4+T cells counts \>500 for more than 7 years since HIV-infection) (LTNP-C) and 40 HIV-controllers non Long Term Non-Progressors (nonLTNP-C) coming from the Spanish AIDS Research Network HIV-Controllers Cohort (ECRIS). We validated these results in 914 white HIV-controllers (52.8% LTNP-C) included in a genome wide association study (GWAS) from the International HIV-controller Study. The IFNL4 polymorphism included in the GWAS was rs12980275 which is in strong linkage disequilibrium with ss469415590 (r^2^=0.901). In a subgroup of patients HIV-specific T-cell response and soluble cytokines array were analysed.

Results {#jve2_5-sec-0003}
=======

After adjusting for sex, age at HIV-diagnosis, favorable IFNL4 genotype, HLA-B27, HLA-B57, HLA-B35 and HLA-B08 haplotypes, the factors independently associated with LTNP-C in both cohorts were favorable IFNL4 genotype (as a risk factor, OR=0.401 (0.171--0.942) *p=*0.036 and OR=0.643 (0.439--0.944) *p*=0.024, respectively) and HLAB-57 (as a protective factor, OR=3.056 (1.029--9.069) *p=*0.044 and; OR=1.909 (1.243--2.931) *p=*0.003, respectively). In the ECRIS cohort it was also associated with sex, while in the International HIV-controller Study there was an association with age at HIV diagnosis. LTNP-C showed lower plasma IP-10, IL-8 and TRAIL levels (*p=*0.019, 0.053 and 0.039, respectively) and higher IL1RA, IFNγ and IL13 (*p=*0.02, 0.016 and 0.05, respectively). Moreover, LTNP-C exhibited higher IL2^+^CD8^+^CD57^-^ and IFNγ^+^CD8^+^CD57^-^ HIV-specific T-cells (*p=*0.002 and 0.041, respectively) than nonLTNP-C.

Conclusions {#jve2_5-sec-0004}
===========

We have unveiled genetic markers able to segregate HIV-controllers into LTNP-C and nonLTNP-C. This finding makes possible to identify those controllers at risk of a CD4 T cell drop and opens the door to potential therapeutical interventions. These results encourage reconsidering LTNP-C as a right model of HIV functional cure.

HIV-1 controllers (including post-treatment controllers)

6 HIV virological controllers in an African cohort
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Background {#jve2_6-sec-0001}
==========

The existence of HIV virological controllers shows that it is possible for the human immune system to robustly control HIV. It is hoped that a better understanding of the mechanisms of control will assist efforts to develop a functional cure. This report describes HIV controllers in an African cohort, examining their features in relation to those of their better-described counterparts in the United States and Europe.

Methods {#jve2_6-sec-0002}
=======

Virological controllers were identified from a prospective seroincidence cohort of young women aged 21--33 years in KwaZulu Natal, South Africa (n=245), and classified as either viraemic or elite controllers (ECs) according to their plasma viral load levels in the absence of antiretroviral therapy (ART). The clinical features, CD4^+^ T cell and viral load trends of the elite controllers were examined in more detail, and their genetic features, including HLA and KIR haplotypes, were sequenced and analysed in relation to existing published data.

Results {#jve2_6-sec-0003}
=======

In the cohort there were 12 viraemic (5%) and 2 elite controllers (1%). The first EC presented post-seroconversion with multiple recurrent infections of the skin, genitourinary tract and tonsils, suggestive of some degree of immune dysfunction. The second displayed no features of HIV-associated morbidity. Both ECs showed an initial viral load spike (33 500 and 741 copies/mL respectively) but shortly thereafter achieved and maintained undetectable plasma viral loads and stable CD4^+^ counts (\>500 cells/mm^3^, average 900 cells/mm^3^) for more than 6 years without ART. Both ECs were found to have HLA haplotypes well-described as being associated with slow progression, most notably HLA-B81\* and HLA-B57\* respectively. Furthermore, the first EC was found to have a KIR2DL2 subtype, also associated with slow progression.

Conclusions {#jve2_6-sec-0004}
===========

While the overall subtype-C infected African cohort differed substantially from subtype-B infected cohorts in other parts of the world, the features of the African elite controllers correspond with those of their international counterparts, in terms of epidemiology, host genetics and associated immunological features. This suggests that progress in HIV controller science may be directly applicable in certain underresearched populations.

Correlates of Immune Protection

7 Presence of HIV-1C broadly neutralizing antibodies in pregnancy and at delivery
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Background {#jve2_7-sec-0001}
==========

HIV neutralizing antibody assays are now being widely employed in different laboratories in search for correlates of protective immunity. There are strong arguments in favor of a beneficial role of some broadly neutralizing antibodies in prevention of HIV infection if these antibodies exist prior to exposure. The neutralizing antibodies could be useful in immunotherapy.

Methods {#jve2_7-sec-0002}
=======

Archived plasma samples collected from 54 mothers at recruitment, before and after delivery from a PMTCT study were assayed for presence of neutralizing antibodies using TZM-bl cells. The participating mothers were divided into HIV transmitters and non-transmitter, indicated at delivery. The virus panel comprised of reference strains (92TH021 and MBA2'- clade AE; 92BR020- clade B; and 93IN905, ZA012, ZM651- clade C, and results were expressed as the plasma inhibition dilution causing 50% or 90% reduction in viral replication.

Results {#jve2_7-sec-0003}
=======

Plasma samples were from 21 non-transmitters and 33 transmitters. Non-transmitters compared to the transmitting mothers had 332 CD4+ cells/μl and 103 024 HIV RNA copies/ml compared to 321 CD4+ cells/μl and 158 164 HIV RNA copies/ml, respectively. Broadly neutralizing antibodies were present in baseline plasma from both HIV-1 transmitters and non-transmitters. When a more stringent cut off value for the neutralizing activity was applied, a decline in the potency and breadth of neutralization was observed in only 2 plasmas showing high 90% infection inhibition of 3 out of 7 strains. Potent neutralizing antibodies to the South African strain (ZA012) were more frequently detected among the non-transmitting mothers. Neutralization titers were significantly higher in non-transmitters for 50% inhibition of the subtype C strains, 93IN905 (p\<0.001) and ZM651 (p=0.014), and for 90% inhibition of 92TH021, MBA2', 92BR020 and 93IN905 (p\<0.001), ZM651 (p=0.006).

Conclusions {#jve2_7-sec-0004}
===========

Despite an overall reduced potency at 90% infection inhibition, non-transmitting mothers had significantly higher potency and breadth (cross-clade neutralization) for 90% viral inhibition at delivery compared to the transmitting mothers. These results provide evidence of the presence of HIV-1 broadly cross-neutralizing antibodies during pregnancy and at delivery that directly could be utilized in the management of HIV infection hence contribute to reduced mother to child transmission.

Viral mechanisms of HIV/SIV persistence and latency

8 IFNα activates latent HIV-1 in non-proliferating latently infected T-cells
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Background {#jve2_8-sec-0001}
==========

Pegylated-IFNα-2a monotherapy in HIV-infected individuals off antiretroviral therapy (ART) leads to a modest reduction in plasma HIV RNA and cell-associated (CA) HIV DNA. While in HIV-infected individuals on ART, it leads to a reduction in CA unspliced HIV RNA. We asked whether IFNα had an effect on the establishment, maintenance and reversal of HIV latency using an *in vitro* model of HIV latency.

Methods {#jve2_8-sec-0002}
=======

Resting CD4^+^ T-cells, labelled with the proliferation dye eFluor670, were cultured with autologous myeloid dendritic cells (mDC) in the presence of staphyloccocal enterotoxin B (SEB) for 24 h and infected with an eGFP-expressing-CCR5-tropic-virus (NLAD8-eGFP). To study the effect of IFNα on the establishment of HIV latency, cells were cultured in the presence and absence of IFNα (1--1000 U/ml) prior to infection. At day 5 post-infection, non-productively-infected, non-proliferating (eGFP^-^eFluor670^hi^) and proliferating (eGFP^-^eFluor670^lo^) T-cells were sorted. Inducible latent infection was quantified by measuring eGFP expression in sorted subsets after activation with anti-CD3/CD28+IL-7+IL-2 in the presence of Raltegravir. To study the effect of IFNα on latency reversal, the above experiments were performed in the absence of IFNα, and once latency was established, cells were cultured in the presence and absence of 100 U/ml of IFNα.

Results {#jve2_8-sec-0003}
=======

IFNα reduced productive infection, with a maximum mean percentage inhibition (MI) of 60% at 1000 U/ml, compared to untreated controls. Latent infection was significantly reduced in non-proliferating T-cells in the presence of 100 U/ml IFNα (MI=62%, p=0.014, n=4), while no reduction was observed in proliferating T-cells. When IFNα was added after latency was established, eGFP expression significantly increased compared to unstimulated controls in non-proliferating cells (mean fold change (MFC) eGFP=1.3, p=0.015, n=8), but not in proliferating T-cells. Surprisingly, when IFNα was added together with anti-CD3/28 to activate eGFP expression in latently infected non-proliferating T-cells, there was a significant reduction in eGFP expression compared to anti-CD3/CD28 alone (p=0.0001, n=8).

Conclusions {#jve2_8-sec-0004}
===========

Using an *in vitro* latency model we have shown that IFNα alone can inhibit productive infection and the establishment of HIV latency *in vitro*, however, once latency*is established* IFNα can also reverse latency in non-proliferating T-cells. IFNα should be explored as a potential therapeutic intervention to perturb latency.

Viral mechanisms of HIV/SIV persistence and latency

9LB HIV-1 disrupts mitochondrial dynamics: induces fission and mitophagy to attenuate apoptosis in astrocyte
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Background {#jve2_9-sec-0001}
==========

The presence of HIV-1 tissue reservoirs, located in the central nervous system, is the main support for HIV-1 chronic infection and the consequent avoidance to virus eradication in HIV-1-infected individuals.

Given the diverse pathophysiological functions of mitochondria during viral infections, understanding the role of mitochondrial dynamics and mitophagy in HIV-infected astrocytes is highly warranted. The present study addressed these challenges and revealed new and opposing phenomena on HIV-infected. Here we demostrate that HIV-1 productive infection on astrocytes can induce aberrant mitochondrial dynamics by mitochondrial fission and subsequent complete mitophagy as a pivotal strategy to subvert imminent apoptosis due to increased mitochondrial injury.

Methods {#jve2_9-sec-0002}
=======

We employed pNL43-DsRed/eGFP, a full-length infectious molecular clone of HIV-1 to infect U373 cells (human astrocytoma cells). It can be monitored on FACS (FACSCanto, BD Biosciences) through the fluorescent reporter gene expression and simultaneously evaluate intracellular ROS level (DCFDA), mitochondrial ROS production (MITOSox), mitochondrial transmembrane potential gradient ΔΨm (TMRM) and apoptosis (Caspase 3 & 7 and Annexin V). All measurements were made simultaneously 3 days post infection.

Mitochondrial fragmentation, autophagy and mitophagy were measured in transfected cells overexpressing RFP-LC3 protein and later infected with HIV-1. Three days post-infection were stained with Mitotracker and evaluated by fluorescence microscopy. Statistical differences were calculated by Student t-test.

Results {#jve2_9-sec-0003}
=======

ROS production was significantly higher in U373 productively infected cells than in neighbor non-infected cells (82±5% vs. 15±3%; p\<0.001). Such ROS level in infected cells appeared to be positively correlated with mitochondrial fission (p\<0.001). Besides, the expression of LC3 protein depicted a punctate distribution pattern allowing inferring the induction of general autophagy that also noticed a colocalization with mitochondria showing formation of mitophagosome. The percentage of ΔΨm-lost, activation of caspases 3 & 7 and Annexin V were significantly higher in U373 non-infected neighbor cells than productively-infected cells (60±5% vs. 5±2%, respectively; p\<0.001).

Conclusions {#jve2_9-sec-0004}
===========

The selective removal of damaged mitochondria is essential for the maintenance of mitochondrial and cellular homeostasis. Here, we report that HIV-1 shifts the balance of mitochondrial dynamics toward fission and mitophagy to attenuate the virus-induced apoptosis in astrocyte.

Host Cellular Factors and Latency

10 The interferon-inducible restriction factor TRIM22 contributes to HIV-1 latency
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Background {#jve2_10-sec-0001}
==========

We have previously demonstrated that the type 1 interferon-inducible restriction factor tripartite motif-containing protein 22 (TRIM22) inhibits HIV-1 replication by acting at the transcriptional level upon acute *in vitro*infection (A. Kajaste-Rudnitski *et al.,* J. Virol. 2011). We have recently determined that TRIM22 prevents the binding of the transcription factor (TF) Sp1 to the viral promoter (F. Turrini *et al.,* Retrovirology 2015). Therefore, we have here investigated whether TRIM22 could also influence the state of HIV-1 latency in chronically infected cell lines carrying integrated proviruses.

Methods {#jve2_10-sec-0002}
=======

TRIM22 mRNA and protein expression were evaluated by qPCR and Western Blotting in chronically infected J-Lat 10.6 and ACH2 T-lymphocytic cell lines. Endogenous TRIM22 was knocked-down (KD) in these cell lines by transduction of a lentiviral vector expressing an shRNA either against TRIM22 or containing a scramble sequence as a control (mock-transduced cells). Reactivation of proviral transcription was assessed by reverse transcriptase activity released in the culture supernatants of either transduced or not-transduced (control) cells stimulated with latency-reversing agents (LRA) such as TNF-alpha, activator of NF-kB, 12-phorbol 13-myristate acetate (PMA), activator of NF-kB and of other TF, or the histone deacetylase inhibitor Trichostatin A (TSA).

Results {#jve2_10-sec-0003}
=======

TRIM22 mRNA was differently expressed in ACH2 and J-Lat 10.6 cell lines (286.4±28.9 vs. 1,313.2±19.6 normalized copies, respectively) and it was efficiently KD at protein level in both cell lines. TRIM22-KD enhanced the basal levels of HIV-l expression in ACH2, but not in J-Lat 10.6 cells. Furthermore, proviral reactivation by cell stimulation with TNF-alpha or TSA, but not by PMA, was further increased in TRIM22-KD T lymphocytic cell lines vs. both mock-transduced and control cells.

Conclusions {#jve2_10-sec-0004}
===========

TRIM22 may play a potential role in the maintenance of HIV-1 latency in ACH-2, but not in J-Lat 10.6 T lymphocytic cell lines whereas its shRNA-mediated downregulation synergized with the LRA TNF-alpha and TSA in both cell lines. As TRIM22 targets Sp1-driven transcription, these results highlight the potential importance of this TF in strategies aiming at purging the pool of latently infected T-cells.

Host Cellular Factors and Latency

11 Identification of a new host cell HDAC complex that controls HIV latency through direct binding to the core promoter
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Background {#jve2_11-sec-0001}
==========

Strategies to achieve a cure for HIV/AIDS will require the therapeutic control of HIV latency whether they involve "shock and kill" activation or "deep latency" repression of HIV transcription. We have previously reported that the HIV core promoter is selectively recognized by cellular pre-initiation complexes of HIV (PICH) via its TATA box and adjacent sequences of HIV essential for Tat *trans*-activation (TASHET) element. To uncover molecular targets to therapeutically control latency we have now identified protein components of PICH and characterized their impact on HIV transcription.

Methods {#jve2_11-sec-0002}
=======

DNA affinity chromatography coupled to mass spectrometry analysis was used to identify host cell PICH proteins that recognize TASHET. Co-immunoprecipitation was used to determine interacting partners of identified PICH proteins. Biophysical techniques including fluorescence anisotropy and circular dichroism (CD) were used to demonstrate direct PICH-DNA interactions. Chromatin immunoprecipitation (ChIP) assays were used to test PICH interactions with the HIV promoter *in cellulo*. siRNA were employed to test the impact of PICH proteins on HIV transcription *in cellulo*. HIV reporter viruses were used to test the requirement of PICH-binding sequences of TASHET for reactivation by latency-reversing agents (LRA) in infected T cells.

Results {#jve2_11-sec-0003}
=======

We identified two new proteins in nuclear extracts from uninfected PBMC, HeLa cells, and Jurkat T cells that specifically bind to the HIV core promoter *in vitro*. These proteins, termed PICH-130 and PICH-37, interact tightly in cells as demonstrated by co-immunoprecipitation. PICH-130 and PICH-37 form part of a HDAC complex of previously unknown function that contains HDAC1 and HDAC2. Strikingly, PICH-37 directly and selectively binds the TATA and adjacent CTGC motifs within TASHET *in vitro*. PICH-37 binds the HIV promoter in infected HeLa and Jurkat cells. siRNA-mediated knock-down of PICH-130 and PICH-37 strongly reduced both Tat-activated and basal HIV transcription *in cellulo*. Intriguingly, mutation of the PICH-37-binding CTGC motifs in reporter virus completely blocked reactivation of HIV by pharmacological LRA that act via the Tat/TAR/7SK axis in T cells, but only partially reduced reactivation by HDAC inhibitors.

Conclusions {#jve2_11-sec-0004}
===========

PICH-37 and PICH-130 form part of a novel HDAC complex that controls HIV latency and is essential for reactivation via the Tat/TAR/7SK pathway.

Cellular and tissue reservoirs of HIV/SIV

12 Persistence of HIV DNA in seminal plasma fraction after ART among men who have sex with men and transgender women in the Thailand test & treat cohort
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Background {#jve2_12-sec-0001}
==========

Semen has been suggested as a potential reservoir for latent HIV infection; however, few studies have investigated the presence of HIV DNA in semen or persistence after ART. We hypothesized that HIV DNA would be detectable in semen specimens after ART initiation and for a longer period afterward compared to HIV RNA.

Methods {#jve2_12-sec-0002}
=======

Semen was collected from Test & Treat participants in Bangkok (Thai MSM and TG women, ≥18 years, no previous HIV-positive tests at baseline) at week 0 of ART initiation as well as month 6 and month 12 afterward. For each specimen, DNA was extracted in separate seminal plasma and sperm fractions by differential lysis. HIV DNA was measured by qPCR for seminal plasma and sperm fractions at week 0 as well as seminal plasma fractions at month 6 and month 12. Paired data was compared, using McNemar\'s test.

Results {#jve2_12-sec-0003}
=======

Out of 91 participants (160 specimens), 21 participants had specimens at 3 timepoints; 27 had specimens at 2 timepoints; 43 had specimens at 1 timepoint. HIV DNA was measurable above the limit of detection as follows: 1/44 (2%) sperm fractions at week 0; 8/44 (18%) seminal plasma fractions at week 0; 5/58 (9%) seminal plasma fractions at month 6; and 3/58 (5%) seminal plasma fractions at month 12. Difference in measurable HIV DNA was statistically significant only when comparing seminal plasma to sperm fractions at week 0 (p=0.02).

HIV RNA was detected in only 1/5 seminal plasma specimens with measurable HIV DNA at month 6 and in 0/3 seminal plasma specimens with measurable HIV DNA at month 12. **Figure 12.1.** HIV DNA copy number at timepoints relative to ART initiation

Conclusions {#jve2_12-sec-0004}
===========

HIV DNA was measurable in seminal plasma fractions at least to month 12 after ART initiation while HIV RNA became undetectable in the same specimens. Further study is necessary to characterize semen as a HIV reservoir and determine reactivation potential and transmissibility.

Cellular and tissue reservoirs of HIV/SIV

13 Memory CD4+ T cells expressing HLA-DR contribute to HIV persistence during prolonged ART
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Background {#jve2_13-sec-0001}
==========

Most measurements of HIV reservoirs are performed using "resting" CD4+ T cells depleted for cells expressing HLA-DR, which is considered an activation marker. However, little is known about the possible role of these cells in HIV persistence during ART. Here, we examine the contribution of memory CD4+ T cells expressing HLA-DR to HIV persistence after prolonged ART (≥15 yrs).

Methods {#jve2_13-sec-0002}
=======

Using LTR-specific qPCR, HIV RNA and DNA were quantified in memory CD4+ T cells expressing HLA-DR or not from 6 participants (P1-P6) on ART (≥15 yrs). Using single-genome/proviral sequencing, we characterized HIV-RNA/DNA (p6-RT) sequences from HLA-DR+ and HLA-DR- memory T cells, central (CM), transitional (TM) and effector (EM) memory T cells. Clonal expansions were defined as ≥2 identical sequences in phylogenetic trees.

Results {#jve2_13-sec-0003}
=======

CD4+ HLA-DR+ and HLA-DR- memory cells contained a median of 3400 and 1000 HIV-RNA copies/million cells; and 36 and 60 HIV-DNA copies/million cells respectively, indicating the HIV transcriptional activity of HLA-DR+ cells is 6-fold higher than HLA-DR-. In participants treated during chronic infection, proportions of HIV-DNA clonal expansions were similar between HLA-DR+ and HLA-DR- memory T cells but HIV-DNA sequences from EM were more often identical to HIV-DNA sequences from HLA-DR+ memory cells (43% P1, 88% P2) than CM and TM (8--18% P1; 8--44% P2; p\<0.0001--0.03). For one participant treated during acute infection, approximately 50% of the sequenced HIV-DNA from HLA-DR- memory T cells, CM, TM, and EM was defective (hypermutated and/or containing stop codons) and 26% of HIV-RNA from HLA-DR- memory T cells was defective. However, the amount of defective HIV-DNA and RNA from HLA-DR+ memory T cells was much lower (21% and 0% respectively).

Conclusions {#jve2_13-sec-0004}
===========

These findings demonstrate that memory CD4+ T cells expressing HLA-DR contain persistent HIV-DNA and measurable HIV-RNA. Furthermore, these cells appear to contain more intact virus in the region sequenced than other cellular subsets. Therefore, measurements of the HIV reservoir during ART should include memory cells expressing activation markers, including HLA-DR. HLA-DR+ and EM cells had clonal expansions of genetically identical HIV-DNA, suggesting these cell subsets replenish the HIV reservoir through proliferation during prolonged ART.

Cellular and tissue reservoirs of HIV/SIV

14 Effect of substances of abuse on HIV DNA decay during antiretroviral therapy started during early HIV infection
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Background {#jve2_14-sec-0001}
==========

Substances of abuse are widely used among HIV-infected men who have sex with men (MSM), and are associated with T-cell activation, greater HIV transcription, and HIV disease progression. We hypothesize that drug use might influence HIV DNA decay after early initiation of antiretroviral therapy (ART).

Methods {#jve2_14-sec-0002}
=======

We investigated 552 peripheral blood mononuclear cell samples from 79 recently HIV-infected MSM from the San Diego Primary Infection Cohort. Participants started ART within a median of 4 months from the estimated date of infection (EDI) (IQR: 2--11) and achieved suppressed HIV RNA within a median of 3 months (IQR: 2--6). Participants were followed for a median of 29 months (IQR: 4--38) while on suppressive ART. Levels of CD4-associated HIV DNA and RNA (unspliced and multiply spliced) were measured by (dd)PCR. Substance use was defined as self-reported drug use within the last 3 months at enrollment (including methamphetamine, γ-hydroxybutyrate \[GHB\], cocaine, alkyl-nitrite \['popper'\], ecstasy, hallucinogens, opiates). Linear mixed-effect regression analysis was used to evaluate associations between use of drugs and changes in log~10~ HIV DNA levels or cellular HIV RNA transcription during ART. Additional tested variables included: age, nadir and current CD4^+^ T-cell counts, peak HIV RNA level, pre-ART HIV DNA level, time from EDI to ART initiation, time from ART initiation to virologic suppression.

Results {#jve2_14-sec-0003}
=======

Drug use was self-reported in 41 participants (52%) and included: methamphetamine (N=20), poppers (N=24), opiates (N=22), ecstasy (N=11), cocaine (N=6), and GHB (N=13). The median peak HIV RNA level was 5.6 log~10~ copies/mL (IQR: 5--6.3) and the median nadir CD4^+^ T-cell count/μl was 420 (IQR: 297--520) with no difference between groups. Following ART initiation, self-reported recreational use of poppers was the only variable associated with a significantly slower decay rate of log~10~HIV DNA (p=0.027). There was no difference in cellular HIV RNA transcription between popper users and non-users.

Conclusions {#jve2_14-sec-0004}
===========

Recreational use of poppers was frequent in our cohort and was the only factor associated with a slower decline of HIV DNA during suppressive ART. The mechanism underlying this association is unclear, but it is likely not attributable to less effective viral suppression on ART in users of poppers.

Cellular and tissue reservoirs of HIV/SIV

15 Is the lung a site of productive HIV infection that persists through ART?
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Background {#jve2_15-sec-0001}
==========

HIV persistence is maintained by viral reservoir(s) discrete from the peripheral viral population. These viral reservoirs are particularly significant during the rebound of peripheral viremia following failure of anti-retroviral therapy (ART). Using Fluorescent *in situ* Hybridization (FISH)-based detection system we demonstrated previously that chronically HIV-infected, ART-naïve individuals have virus in their lungs that is present predominantly in alveolar macrophages (AM). AM are long-lived cells that could represent an under-appreciated reservoir for HIV.

Methods {#jve2_15-sec-0002}
=======

HIV mRNA was detected by FISH. The ability of cells isolated by bronchoalveolar lavage (BAL) to generate infectious virus was probed using a novel reporter cell line (TZM-GFP) engineered to express GFP in a tat/rev-dependent manner. Further characterization of the co-receptor utilization of these viral populations is being conducted using the Affinofile cell line expressing differing levels of CD4 and CCR5.

Results {#jve2_15-sec-0003}
=======

Here we show that AM from Malawian HIV-1-infected adults who had been on ART for extended periods (\>4 yrs) remain positive for HIV-1 *gag* mRNA. The majority of these individuals possess a plasma viral burden below the limit of detection. To probe for production of infectious virus, we used a reporter cell line that exhibited HIV tat/rev-dependent expression of GFP and was permissive to infection when co-incubated with HIV-1-positive human monocyte-derived macrophages (HMDM) in culture. When co-cultured with BAL cells from ART-naïve HIV-infected individuals we could readily detect infection of the fluorescent reporter cell line. Furthermore, we also demonstrated production of infectious virus in individuals on extended ART, who lacked peripheral viremia but had detectable HIV-1 *gag* mRNA in their AM. The further characterization of the cell-tropism and infectious characteristics of this viral population is currently under investigation using Affinofile cells under differing levels of induction of CD4 and CCR5.

Conclusions {#jve2_15-sec-0004}
===========

AMs are extremely long-lived cells that are not killed by HIV-infection. This raises the possibility that HIV-1-infected AM could contribute to the maintenance of productive HIV infection that persists through long-term ART. Phenotypically, with respect to the evolution of viral diversity, drug suppression of transcriptionally-active, HIV-infected AMs by ART would be indistinguishable from the arrested genomic diversity observed as a result of latent infections.

Cellular and tissue reservoirs of HIV/SIV

16LB Whole-body SPECT in Vivo Imaging reveals delayed reconstitution of lymph-nodes, but not spleen, CD4 pools in long-term cART treated animals
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Background {#jve2_16-sec-0001}
==========

Fewer than 2% of the total-body-pool of CD4+ T lymphocytes reside in the peripheral-blood (PB) highlighting the need for techniques that provide a more comprehensive evaluation of the immune system. In previous work we demonstrated the feasibility of imaging the total-body-CD4-pool in nonhuman-primates and noted that the CD4-pool of splenic lymphocytes may increase or decrease by up to 30% within 4 weeks of initiation or interruption of cART, respectively. The present study was designed to more carefully delineate the relationships between viremia, PB CD4-count and total-body-CD4+ pool.

Methods {#jve2_16-sec-0002}
=======

A group of 30 rhesus macaques (uninfected and SIV/SHIV infected with PB-CD4 count range (7--1718) cells/μl) were subjected to a total of 59 SPECT imaging studies, using the F(ab′)2 fragment of anti-CD4 labeled with Tc-99m. Six of the SIV-infected animals had been treated with cART for more than 5 months with SIV RNA levels \<30 copies/ml in 5 animals and 950 copies in the other. Linear mixed-effect models with random intercepts were used for longitudinal analyses.

Results {#jve2_16-sec-0003}
=======

A repeated measurements univariate analysis of all animals revealed that both PB-CD4-count and plasma-viral-load were significantly associated with the size of the splenic CD4 pool (P\<0.001). The PB-CD4-count was also univariately associated with the size of the CD4-pool of the axillary, inguinal and sub-mandibular lymph-nodes (all P\<0.01). Only the size of the sub-mandibular pool was also associated with plasma-viral-load (P=0.046). In a multivariate analysis, adjusting for the PB-CD4-count, only the size of the splenic CD4-pool remained associated with the plasma-viral-load (P=0.01).

Compared to healthy controls (n=11, mean PB-CD4 count 962 95%C.I. (773--1151) cells/μl), long-term cART-treated animals (n=6, 691 95%C.I. (235--1147) cells/μl) had smaller axillary (P\<0.05) and inguinal (P\<0.05) lymph-nodes CD4-pools but similar levels of sub-mandibular and splenic CD4-pools. Of note the anti-CD4 radiotracer uptakes of the axillary and inguinal lymph-nodes of an animal with a long-term non-progressor phenotype were observed to be two-fold higher than the average of healthy-controls.

Conclusions {#jve2_16-sec-0004}
===========

Despite similar sizes of splenic CD4 pools, the sizes of the pools of CD4 cells in the peripheral lymph nodes of treated animals were smaller than those in healthy controls

Measurement of HIV/SIV reservoirs

17 HIV proviral DNA quantification in a cohort of Japanese patients on long-term ART
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Background {#jve2_17-sec-0001}
==========

Despite successes of ART, persistence of HIV reservoir and its measurement remain unsolved issues. Understanding the integrated viral DNA and the mechanisms of persistence are important for the future HIV cure, especially in long-term treated patients. Therefore, our aim was to evaluate the total HIV DNA (viral reservoir in PBMC) in a cohort of Japanese patients on ART.

Methods {#jve2_17-sec-0002}
=======

A retrospective study of PBMC samples collected from 155 patients (91% male, average age 47 years) of Kumamoto University hospital in the period 1996--2015 was performed. Longitudinal clinical data was collected and long-term treated suppressed patients were selected. PBMC DNA was extracted via standard methods (Qiagen kit) and run in a quantative PCR (SYBR green setting as modification of previously described method by Douek et al. (2002) with plasmids used as standards in serial dilutions). qPCR data was analyzed and total proviral DNA copies/10∧6 PBMC were calculated. Patients were divided in groups by current ART regimen and effects of long-term treatment on the PBMC reservoir were observed.

Results {#jve2_17-sec-0003}
=======

Although the levels of total proviral DNA were quite low (mean 104 copies/10∧6 PBMC), a tendency towards a constant plateau level was observed in the majority of patients, all under successful ART. Most of the proviral loads detected were in the cluster of 20 and 200 copies/10∧6. Despite ART and clinical VL\<20 copies, integrated HIV DNA persistence was readily detected in patients at relatively constant values. DNA load fluctuations were observed upon ART initiation, but rarely within stable ART. Rises in total DNA were observed, but a decline below a certain plateau level for each patient was not detected. There was no significant correlation between plasma VL and DNA load dynamics.

Conclusions {#jve2_17-sec-0004}
===========

Our data identifies some of the patterns of reservoir persistence in PBMC, aiming at accumulating a library for a number of patients and basis for further evaluations on the influencing factors. Its quantification in patients' blood samples was relatively easy to perform and could be clinically implemented as monitoring tool. The patterns of integrated DNA persistence may be a key to eradication studies and viral infection course prognosis.

Measurement of HIV/SIV reservoirs

18 Initiation of ART within 24--48 hours of birth following in utero HIV infection: the Ucwaningo Lwabantwana Study
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Background {#jve2_18-sec-0001}
==========

Prevention of mother-to-child transmission of HIV has reduced transmission rates to 1--2%, with \~6,000 babies HIV-infected/year in South Africa. There is increasing evidence that early anti-retroviral therapy, especially in in utero infected children, is effective in reducing the size of the HIV reservoir. The aim of this study is, first, to evaluate the feasibility of identifying in utero HIV-infected babies and initiating ART within the first 24 to 48 hours of life. Subsequently it will be determined whether early initiation of ART results in substantially lowered viral reservoirs over the course of time.

Methods {#jve2_18-sec-0002}
=======

Babies "at high risk" of HIV infection were defined by (1) born to HIV-infected mother; and (2) mother\'s ART interruption, seroconversion and/or ART initiation during pregnancy. HIV PCR testing of the newborn was performed using the Cepheid GeneXpert assay. If tested positive, ART was initiated inmediately according to South African treatment guidelines. The babies are followed up monthly within the first 6 months of life and subsequently three monthly . Studies of the viral reservoir in peripheral blood will be performed accordingly.

Results {#jve2_18-sec-0003}
=======

The study is conducted at Stanger and Edendale hospitals. Between 24. July and 31 December 2015, 1186 HIV-infected mothers (39% of live deliveries) gave birth at the Stanger site. 710 (60% of HIV-infected mothers) were screened by the study team; 120 babies were tested with the GeneXpert machine. Six babies (5%) were tested HIV-positive and subsequently enrolled in the study. In one of the cases ART initiation within 4 hours of life lead to a decline of viral load from 12,000,000 cp/ml to \<20 cp/ml within 3 months of age. In Edendale, of a total of 1608 live deliveries since 1. October 2015 618 were HIV positive (38.4%). 207 mothers were screened and POC testing performed in 31 of the newborns without positive result so far.

Conclusions {#jve2_18-sec-0004}
===========

Point-of care testing of babies born "at-high-risk" of being HIV-infected is feasible and leads to early ART initiation within the first 24 hours of life. In future, additional therapeutic strategies such as broadly neutralizing antibodies to the ART regimen may facilitate subsequent "cure" in the enrolled infants.

Measurement of HIV/SIV reservoirs

19 Quantification and correlates of the replication competent HIV-1 latent viral reservoir in a virally suppressed Ugandan population
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Background {#jve2_19-sec-0001}
==========

HIV-1 persists in latently infected cells resting memory CD4+ T cells, which is the major barrier to curing infection. Previous studies have quantified this pool of latently infected cells in North Americans and Europeans; however, no study has quantitated the latent HIV-1 reservoir (LVR) in sub-Saharan Africans, who make up the largest population of HIV-infected individuals globally.

Methods {#jve2_19-sec-0002}
=======

Peripheral blood was collected from 30 virally suppressed HIV-infected individuals from Rakai, Uganda, who initiated ART during chronic infection (nadir CD4 count 76--192 cells/μl) and had an undetectable viral load (≤40 copies/μl) for a minimum of 18 months before enrolment. Resting CD4+ T cells were isolated by negative selection. The quantitative viral outgrowth assay (Q-VOA) was used to determine the minimum frequency of latently infected cells with replication competent virus. Multivariate regression analysis was used to identify correlates of LVR size.

Results {#jve2_19-sec-0003}
=======

The median LVR size in this Ugandan population was estimated to be 0.31 IUPM (Infectious Units per Million; range 0.037--8.15 IUPM). LVR size correlated positively with pre-ART viral load (p=0.003) and the number of times plasma viral load became transiently detectable (\>400 copies/μl) after initial ART-suppression (p=0.031). The LVR correlated negatively with CD4:CD8 T cell ratio (p=0.032). LVR size did not correlate with age, gender, duration of viral suppression, nadir CD4 count or CD4 count at the time of Q-VOA. Analyses of viral subtype sequences isolated from the supernatants of p24+ wells of the Q-VOA are ongoing. Of note, the LVR size in this Ugandan population is over 3-fold smaller than that previously reported in Americans (Margolis *et al.*JID 2015).

Conclusions {#jve2_19-sec-0004}
===========

We report the first quantification of latently infected resting CD4+ T cells with replication competent virus in an ART treated, virally suppressed sub-Saharan African population. LVR size correlated positively with pre-ART viral load and transient viral detection, and correlated negatively with CD4:CD8 T cell ratio. LVR size was smaller than previously reported in an American population; further studies will determine if this is attributable to differences in sample handling or other covariates, such as viral subtypes.
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20 Sirtuin1 inhibitor nicotinamide disrupts HIV-1 latency
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Background {#jve2_20-sec-0001}
==========

Quiescent, integrated, replication competent latent provirus is the biggest hurdle in sterilizing cure. This latent pool doesn\'t diminish unless the cells carrying it die by apoptosis or be succumbed to cytopathic effect once viral replication is induced by antigenic stimuli. In the walk of breaking this dormancy of HIV, various histone dependent and independent activators and inhibitors are being used to flush this latent reservoir. Nicotinamide (NAD) is a Sirtuin1 (Class III deacetylase) inhibitor. Sirtuin1 naturally deacetylases p65 subunit of NFKB which being deacetylated cannot recruit P-TEFb on LTR. NAD blocks this pathway facilitating recruitment of TFs and Polymerase II to LTR of HIV, thus breaking latency in an antilatent fashion and creating a hyper activation cell state.

Methods {#jve2_20-sec-0002}
=======

CD8T-cell depleted PBMCs isolated from 15 HIV^+^antiretroviral-treated patients with undetectable viral loads over a period of two years were used.We measured HIV-1 recovery in ex-vivo cell cultures first activated by PHA and treated with NAD for 48 hours and then cultivated in RPMI medium supplemented with IL-2 and fetal bovine serum. While CD8^+^T-cell depleted PBMCs activated with PHA alone and then cultivated in RPMI medium supplemented with IL-2 and fetal bovine serum were used as control samples.

Results {#jve2_20-sec-0003}
=======

NAD induced purging in 12 out of 15 subjects. Three days after treatment with NAD, culture supernatants were tested for viral load using qPCR and the results revealed HIV-1 emergence from day 4^th^- day 18^th^ (median 7 days) with viral load from 2.5 log10 to 7.0 log10 (median of 6.2), whereas viruses were not detected in control experiments. Relating viral emergence with clinical parameters showed that culture positivity is independent of CD4+T cell nadir, time of viral load below detection limits, antiretroviral scheme and viral tropism.

Conclusions {#jve2_20-sec-0004}
===========

Certain Sirtuin substrates can be tied to pathogenesis of diseases (like cancer) infections (HIV-1) and metabolic disorders. Hence NAD, being inhibitor of Sirtuin1, can be promising in flushing out the reservoirs. Since NAD is also depleted in HIV-1 patients, it may further help in regulating the redox environment, without any significant toxicity.
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21 T regulatory cell depletion in controller macaques reactivates SIV and boosts CTLs
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Background {#jve2_21-sec-0001}
==========

T regulatory cells (Tregs) may be involved in formation of latent reservoir, being susceptible to HIV/SIV infection. Resting Tregs harbor high levels of HIV/SIV. During acute infection, Tregs decisively contribute to the establishment of HIV reservoir by reversing CD4+ T cell immune activation status. During chronic infection, they contribute to the impairment of CTL responses, as Treg expansion correlates with loss of CTL function and their ex vivo depletion enhances T cell responses to HIV/SIV antigens. HLAB27+and B57+ HIV-specific CD8+ T cells from elite controllers evade Treg suppression. We hypothesized that Treg depletion is a valid approach for HIV cure, in which a single intervention reduces the size of the reservoir, reactivates the virus and boosts cell-mediated immune responses.

Methods {#jve2_21-sec-0002}
=======

Five SIVsab-infected RMs, in which spontaneous supercontrol of virus replication (\<3 copies/ml plasma) associates complete control of immune activation, were depleted of Tregs with Ontak (Denileukin diftitox), an engineered protein combining IL-2 and diphtheria toxin. Treg depletion was monitored by flow cytometry and immunohistochemistry; plasma viral load was measured by single copy assay; specific cellular immune responses to SIV antigens were monitored flow-cytometrically by intracellular cytokine staining after stimulation with SIVsab peptides.

Results {#jve2_21-sec-0003}
=======

Ontak administration to SIVsab-infected RMs resulted in significant depletion (\>75%) of the circulating Fox-P3+CD25+CD4+ T cells. Up to 60% and \>50% of Tregs were depleted from gut and the lymph nodes, respectively. Ontak impact on overall CD8+ T cell counts was minimal. Treg depletion resulted in a major increase of the levels of CD4+ T cell activation (Ki-67). In the absence of antiretroviral therapy, virus rebound to 103 vRNA copies/ml of plasma occurred after Ontak administration. Importantly, Treg depletion resulted in a significant boost of the SIV-specific CD8+ T cells and rapid clearance of the reactivated virus.

Conclusions {#jve2_21-sec-0004}
===========

Treg depletion in chronically SIV-infected superelite controller RMs resulted in both reactivation of latent virus and a boost of CTL responses. The overall Treg ability to control immune responses was significantly impaired despite the fact that Treg depletion was incomplete. As no latency reversing agent in development has such a dual activity, our strategy holds great promises for cure research.
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22 Development of DOUBLE NICKASE CRISPR aganist latently infected human immunodeficency virus (HIV)
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Background {#jve2_22-sec-0001}
==========

Human immunodeficiency virus (HIV) is a global concern due to increase in prevalence particularly in developing countries and an increasing number of deaths every year. This is attributed to lack of prophylactic measures and long term treatment strategies.

Description {#jve2_22-sec-0002}
===========

While HAART works efficiently to reduce viral load, it is incapable of eradicating the latent reservoirs of the virus. Genome editing tool, clustered regulated interspaced palindromic repeats (CRISPR) discovery in bacteria may be a solution to this problem due to its high specificity and efficacy, a challenge faced by other tools like Zinc finger nuclease (ZFNs), RNA interference (RNAi) and transcription activator-like effector nucleases (TALENs).

Lessons learned {#jve2_22-sec-0003}
===============

Using type II CRISPR/cas9 bioengineered nickase system PX335-U6-D10A with an inactivated nuclease functional domain, Gag and Rev that mediate attachment, entry and provirus assemblage were targeted in order to disrupt their function by creating a double strand break (DSB). Results obtained showed mismatched nucleotide sequences created by non-homologous DNA repair mechanism in the cell. These indels were checked using PCR surveyor and p24 Elisa assay to quantify viral replication.

Conclusions/Next steps {#jve2_22-sec-0004}
======================

Based on this study, we concluded and propose CRISPR/cas9 as a sensitive, specific, precision tool for future treatment for infectious diseases. However, development of advanced genetic sequences alignment and specificity calculation is required for quality precision and off targets check in the human genome.
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23 Understanding the effects of latency reversing agents on HIV RNA splicing: implications for latency reversal
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Background {#jve2_23-sec-0001}
==========

Latency reversing agents (LRAs) are currently under investigation as part of a strategy for an HIV cure. Histone deacetylase inhibitors (HDACi) increase transcription of unspliced (US) HIV RNA but have limited potency in vivo. We investigated whether this may arise from impaired splicing of HIV RNA. We determined the effect of LRAs on HIV RNA splicing in the presence and absence of HIV Tat protein, which impacts splicing alongside transcription.

Methods {#jve2_23-sec-0002}
=======

We employed an LTR-driven splicing reporter construct where HIV Envelope gp140 is fused to eGFP and is expressed if the RNA transcribed from the reporter remains unspliced. If the RNA is spliced across the naturally occurring splice donor-4 and acceptor-7 within *env*, then a Rev mutant fused to dsRed is expressed instead. This system therefore allows the detection of unspliced and spliced RNA products through the measurement of eGFP or dsRed via flow cytometry. HEK293T-cells were transfected with the reporter construct with or without a Tat expression plasmid and treated with a panel of LRAs. Fluorescence was assessed and Paired T-tests were performed.

Results {#jve2_23-sec-0003}
=======

In cells transfected with the splicing reporter, treatment with romidepsin, panobinostat, JQ1 and PMA/ionomycin significantly increased the expression of unspliced product compared to DMSO in the absence of Tat (4.3, 1.6, 2.9, 6.8 fold change (FC) respectively, all p\<0.05) and in the presence of Tat (1.5, 1.7, 1.5, 1.2, 1.7 FC respectively, all p\<0.05). Interestingly, without Tat only JQ1 and PMA/ionomycin significantly increased the expression and proportion of spliced product (dsRed/(dsRed+eGFP)) (4.9, 4.6 FC respectively, both p\<0.05). Conversely, although HDACi had no effect on the level of spliced product without Tat, when Tat was added, a significant reduction in the proportion of spliced product was observed following treatment with vorinostat, romidepsin and panobinostat compared to DMSO (0.54, 0.62, 0.76 FC respectively, all p\<0.05).

Conclusions {#jve2_23-sec-0004}
===========

HDACi reduce the efficiency of HIV RNA splicing in the absence or presence of Tat. This was not seen with other LRAs including JQ1 and mitogen. In addition to the effect of LRAs on HIV transcription, we propose that an assessment of RNA splicing should also be evaluated.
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Background {#jve2_24-sec-0001}
==========

Chronic immune activation is a hallmark of HIV infection, one of the triggers of which is the breach in the integrity of mucosal immune system and microbial translocation which in turn determines the rate of progression to AIDS.Thalidomide is a derivative of glutamic acid that besides being an inhibitor of TNF-α and having an anti-inflammatory property has immunomodulatory and anti-oncogenic properties as well. Thalidomide and its analogues have been shown to have phosphorylation activity of certain transcription factors (TFs) and cell surface receptors, involved in cell signaling. Since HIV transcription utterly needs active cell state with upregulated TFs and their access to viral genome, we tested Thalidomide for its potential in reactivating HIV-1 from latency.

Methods {#jve2_24-sec-0002}
=======

CD8T-cell depleted PBMCs isolated from 15 HIV^+^antiretroviral-treated patients with undetectable viral loads over a period of two years were used.We measured HIV-1 recovery in ex-vivo cell cultures first activated by PHA and treated with thalidomide for 48 hours and then cultivated in RPMI medium supplemented with IL-2 and fetal bovine serum. While CD8^+^T-cell depleted PBMCs activated with PHA alone and then cultivated in RPMI medium supplemented with IL-2 and fetal bovine serum were used as control samples.

Results {#jve2_24-sec-0003}
=======

Thalidomide induced purging in 6 out of 7 subjects. Second day after treatment with Thalidomide, culture supernatants were tested for viral load using qPCR and the results revealed HIV-1 emergence at day 4^th^ with viral load from 2.2 log10 to 6.0 log10 (median of 5.7),whereas viruses were not detected in control experiments. Relating viral emergence with clinical parameters showed that culture positivity is independent of CD4+T cell nadir, time of viral load below detection limits, antiretroviral scheme, viral tropism and subtype of virus.

Conclusions {#jve2_24-sec-0004}
===========

Our results show that Thalidomide is causing purging of HIV by an unknown mechanism so therapeutic manipulation with this drug can generate particular interest. A better understanding of its pharmacology and its sensitive targets is needed to harness the full potential of this agent in HIV-infection.
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25 Targeting HSF1-mediated stress response can enhance Hsp90 inhibitor-induced suppression of HIV-1 reactivation from latency
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Background {#jve2_25-sec-0001}
==========

The state of latency, when HIV-1 persists in cellular reservoirs, allows the virus to avoid eradication and be reactivated afterwards. It was previously shown that heat shock protein 90 (Hsp90) is required for HIV-1 reactivation from latency, so that inhibitors of the Hsp90 chaperone activity can suppress this reactivation and be considered as anti-AIDS agents. Taking into account that the Hsp90 dysfunction provokes the heat shock transcriptional factor-1(HSF1)-mediated up-regulation of inducible Hsp90, Hsp70, Hsp27, MDR1/Pgp, we hypothesized that such accumulation of stress-proteins in cellular reservoirs somewhat assists the virus and impairs the beneficial effects of Hsp90-inhibiting treatments. Here we examined whether the suppressive action of Hsp90 inhibitors on the HIV-1 reactivation can be enhanced by targeting HSF1.

Methods {#jve2_25-sec-0002}
=======

The HIV-1 reactivation was studied in cultured J-Lat cells. 17AAG and AUY922 were used as cell-permeable inhibitors of Hsp90. The HSF1-mediated stress-response in the Hsp90 inhibitor-treated cells was blocked by co-treatments with quercetin or KNK437. Expression of the (co)chaperones and inducible stress-proteins was analyzed by immunoblotting and imunoprecipitation.

Results {#jve2_25-sec-0003}
=======

It was found that inhibition of the Hsp90 chaperone activity with 17AAG or AUY922 does suppress the HIV-1 reactivation in the drug-treated cells; however, this is also accompanied by the HSF1 activation and up-regulation of the cellular levels of inducible chaperones (Hsp90, Hsp70 and Hsp27) and Pgp (a drug-excluding membrane pump). In the case of inhibitory co-treatments (17AAG or AUY922 + quercetin or KNK437), no increase in the cellular levels of inducible stress-proteins or Pgp took place despite of the dysfunction of Hsp90-dependent chaperone machine. Importantly, such a combination of the two inhibitors simultaneously targeting the Hsp90 activity and the HSF1-mediated stress response stronger suppressed the chaperone-dependent HIV-1 reactivation from latency, as compared with the action of Hsp90 inhibitors alone.

Conclusions {#jve2_25-sec-0004}
===========

The suppressive effects of Hsp90-inhibiting drugs on the HIV-1 reactivation from latency are partly impaired by the newly induced chaperones and Pgp. Herein, the beneficial action of Hsp90 inhibitors can be enhanced by parallel inhibiting the HSF1-mediated stress response.
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26 A novel assay to evaluate the response of patient-derived virus to latency-reversing agents

ex vivo

Lu

H.

1

Moso

M.

1

2

Gray

L.

2

3

Mota

T.

1

4

Jacobson

J.

1

4

Ellett

A.

3

Cheng

W.-J.

3

Purcell

D.

1

4

Cameron

P.

1

2

Churchill

M.

2

3

5

Lewin

S.

1

2

Peter Doherty Institute

,

University of Melbourne

,

Melbourne

,

Australia

,

Monash University

,

Department of Infectious Diseases

,

Melbourne

,

Australia

,

Burnet Institute

,

Centre for Biomedical Research

,

Melbourne

,

Australia

,

University of Melbourne

,

Microbiology and Immunology

,

Melbourne

,

Australia

,

Monash University

,

Department of Microbiology

,

Melbourne

,

Australia

Background {#jve2_26-sec-0001}
==========

Despite antiretroviral therapy (ART), HIV latency remains a major barrier to cure. One strategy to eliminate latently infected cells is to stimulate virus production from latency. Latency-reversing agents (LRAs) have been shown to be highly potent *in vitro*, however their efficacy in activating latent HIV is highly variable *ex vivo* and *in vivo*. We developed a novel model of HIV latency to test the efficacy of LRAs on patient-derived viruses.

Methods {#jve2_26-sec-0002}
=======

Integrated HIV long terminal repeats (LTRs) isolated from CD4^+^ T-cells of four ART-treated patients were cloned into a modified HIV lentiviral vector, pGBFM-nefFluc. Vesicular stomatitis virus G glycoprotein pseudotyped viruses were generated for infection of activated primary CD4^+^ T-cells. Cells were cultured for 10--12 days post-infection and then negatively sorted by flow cytometry based on size and expression of the activation markers CD69, CD25 and HLA-DR. The activity of LRAs (vorinostat, panobinostat, romidepsin, JQ-1 and chaetocin) on HIV transcription was measured by quantification of luciferase activity.

Results {#jve2_26-sec-0003}
=======

After prolonged culture of infected cells, we identified 3 populations of cells based on size and activation marker expression. In the large (blast) CD69^+^/CD25^+^/HLA-DR^+^ T-cells, luciferase expression persisted but in the CD69^-^CD25^-^HLA-DR^-^ blasts, luciferase activity was downregulated. There was minimal luciferase expression from the small (non-blast) cells. Following mitogen re-stimulation, luciferase expression increased maximally in the CD69^-^CD25^-^HLA-DR^-^ blasts, consistent with the establishment of latency within these cells.

Following infection with pseudotyped viruses containing either NL4-3 or patient-derived LTRs, we showed that the LRAs romidepsin and chaetocin had the most potent effect on LTR reactivation. Finally, there was no difference in the response to the LRAs following infection with pseudotyped viruses containing patient-derived LTRs.

Conclusions {#jve2_26-sec-0004}
===========

We have generated a new model of post-activation HIV latency to screen LRAs using patient-derived LTR viruses. In these patients, the LTR sequence alone did not determine the potency of response to an LRA.
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27 Therapeutic immune recovery prevents emergence of CXCR4-tropic HIV-1
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Background {#jve2_27-sec-0001}
==========

In the absence of therapy CXCR4-tropic HIV increases over time, associated with an accelerated disease progression. In most successfully treated patients the situation is quite different: The majority harbors CCR5-tropic variants in the circulation. As antiretroviral therapy itself may be responsible for reducing CXCR4-tropic HIV-1 this study aimed at monitoring the abundance of CXCR4-tropic viral sequences in infected cells during suppressive antiretroviral therapy.

Methods {#jve2_27-sec-0002}
=======

For a group of patients in the Swiss HIV Cohort Study with documented suppressive ART, all carrying subtype B virus, the relative frequencies of CXCR4-tropic proviral HIV-1 variants in circulating PBMC were assessed by next-generation sequencing and interpretation by Geno2Pheno (FPR 3.5%, R5=X4\<%) before and after treatment initiation. Aside from a continuous viral suppression a steady CD4 T cell recovery under cART were was documented for all patients. Viral phylogenetics and evolution were analysed.

Results {#jve2_27-sec-0003}
=======

In 28 of the 35 patients (80%) we observed that frequencies of CXCR4-tropic provirus decreased or in fewer remained stable under therapy. This is in contrast to the situation in untreated patients. In the 7 other individuals (20%) the frequency of CXCR4-tropic provirus increased. In all these latter cases a single viral variant emerged, which was already detectable at time points before therapy initiation. Although a certain proviral sequence evolution was demonstrable in \>50% of all patients under therapy this growing diversity was not associated with a similar frequency increase of CXCR4-tropic proviruses.

Conclusions {#jve2_27-sec-0004}
===========

Our study demonstrates that under successful therapy particularly those cells that are infected with CXCR4-tropic HIV decline in most patients, leading to an overrepresentation of CCR5-tropic provirus. This indicates a preferential pressure on cells harboring CXCR4-tropic envelops. Such a progressive proviral reduction in the immune-competent host could eventually lead to the selective depletion of the pool of CXCR4-tropic HIV in successfully treated individuals, paralleling the improving immune response. A better understanding of the underlying mechanism and of the involved cell types may provide crucial information for the new strategies towards HIV eradication.
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28 Dendritic cells programmed by inflammatory mediators can effectively induce both the immunologic 'kick' and 'kill' of latent HIV-1
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Background {#jve2_28-sec-0001}
==========

While dendritic cells (DC) have been used safely in the clinic as a means of inducing CTL responses in the settings of cancer and HIV, recent *in vitro* and *in vivo* evidence suggest that they may also play a role in HIV-1 latency reversal. Of significance, we recently showed that a DC-based HIV-1 vaccine increased residual viremia in cART-suppressed individuals following analytic treatment interruption. Here we investigate the degree to which DC maturation/polarization status affects the ability of DC to promote both HIV-1 latency reversal and CTL targeting of autologous HIV-1 reservoir antigen.

Methods {#jve2_28-sec-0002}
=======

Using HIV-1-infected Multicenter AIDS Cohort Study participants on cART, and our previously published culture methods, we generated differentially polarized monocyte-derived DC, as characterized by their combined surface expression of CD83, CD86, CCR7, OX40L, Siglec-1, and their IL-12p70 producing capacity. These DC were loaded with autologous HIV-1 antigen and used to test their ability to induce HIV-1 specific cytolytic CD8^+^ T cells (CTL). The DC were also tested for their ability to induce HIV latency reversal by co-culture with autologous CD4^+^ T cells in the absence or presence of Efavirenz and/or antigen (SEB), respectively. Cellular and culture supernatant viral RNA content was quantified by qRT-PCR.

Results {#jve2_28-sec-0003}
=======

Type 1-polarized DC (DC1), which were generated using a combination of inflammatory mediators and characterized by their increased expression of CD83/CD86/Siglec-1/CCR7 and IL-12p70, effectively induced both CTL responses and increases in transcription of proviral DNA from CD4^+^ T cells. Importantly, the increase in HIV-1 replication observed using DC1 was antigen-dependent. In contrast, IL-12p70-deficient, OX40L-expressing, type-2-polarized DC (DC2) generated in the presence PGE~2~ exhibited a decreased capacity to either induce HIV-1-specific CTL responses or to promote HIV-1 latency reversal.

Conclusions {#jve2_28-sec-0004}
===========

The ability of DC to promote either the 'kick' or 'kill' of the latent HIV-1 reservoir is greatly influenced by their maturation/polarization status. We show that DC1 are superior to DC2 in both functions. This critical information is currently being used in development of a potentially effective personalized DC1-based immunotherapeutic approach towards curing HIV-1 infection.
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Background {#jve2_29-sec-0001}
==========

The latent reservoir in resting CD4+ T cells presents a major barrier to HIV cure. Latency-reversing agents (LRAs) are being developed with the goal of disrupting the latent state, resulting in induction of HIV expression and clearance of infected cells.

Methods {#jve2_29-sec-0002}
=======

In vivo evaluation of HIV persistence and quantification of the HIV reservoirs were performed essentially as we have previously described (Denton et al J. of Virol. 85:7582, 2011 and Denton et al PloS Pathogens 10:e1003872, 2014).

Results {#jve2_29-sec-0003}
=======

We have investigated the in vitro and systemic in vivo effect of panobinostat, a clinically relevant HDACi, on HIV latency. We show that panobinostat induces histone acetylation and HIV promoter expression using well-characterized in vitro systems. Further, we show that panobinostat induces HIV RNA expression within human primary lymphocytes and that it allows the outgrowth of replication-competent virus ex vivo from resting CD4+ T cells of infected, suppressed patients. Next, we demonstrate that panobinostat induces systemic histone acetylation in vivo in the tissues of BLT humanized mice. Finally, we evaluate the effect of panobinostat on systemic cell-associated HIV RNA and DNA levels and the total frequency of latently infected resting CD4+ T cells. Panobinostat treatment did not affect the levels of cell-associated HIV RNA, cell-associated HIV DNA, or latently infected resting CD4+ T cells. These results suggest that combination therapies may be necessary to clear latent infection and demonstrate the resilience of the latent HIV reservoir present in vivo.

Conclusions {#jve2_29-sec-0004}
===========

Together, these results highlight the relatively modest activity of panobinostat in reversing latency *in vivo* in BLT mice and *in vitro* using human samples. They also indicate that HIV eradication using only a single HDACi for latency reversal might not be an effective strategy. Rather, our results strongly support strategies outlined in recent reports that combination therapies with other latency-reversing agents or with targeted cytotoxic agents may be necessary. The need for the evaluation of latency-reversing agent combinations requires a rational and comprehensive approach where the individual contribution of each agent alone is evaluated, and animal models will be critical for testing their safety and efficacy and for accelerating progress toward an HIV cure.
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Background {#jve2_30-sec-0001}
==========

We have previously shown that maraviroc activates NF-kB and target genes in resting CD4^+^-T-cells cells from suppressed HIV-1-infected when added for 10 days to a stable antiretroviral regimen. In order to confirm these results and expand our findings, ten additional patients have included in this clinical trial.

Methods {#jve2_30-sec-0002}
=======

MARAVITRANS is a clinical trial of 10 days MVC intensification in 20 ART-suppressed HIV-1-infected patients. Blood was collected at baseline, after 1, 3 and 10 days on MVC and 18 days after MVC withdrawal. NF-kB, NFAT and AP-1 activation in resting CD4^+^-T-cells were detected by ELISA. NF-kB regulated gene expression was measured by real-time PCR. Cell-associated HIV-1 unspliced RNA (usRNA) was quantified in resting CD4^+^-T-cells by real-time PCR.

Results {#jve2_30-sec-0003}
=======

All patients completed full MVC dosing and follow up. During the 10 days of MVC intensification and compared to baseline, 16/20 patients had an increase in NF-kB activation in resting CD4^+^-T-cells (median fold-change, 1.24, IQR 0.7--2.2); this activation persisted after drug withdrawal in some patients (day 28). Upregulation of at least one NF-kB target gene, particularly TNF-α, was observed in cases where activation NF-kB was shown. No significant NFAT or AP-1 activation was observed during MVC intensification. usRNA was detected at baseline in resting CD4^+^-T-cells in all the patients (mean: 101.7 copies/10^6^ resting CD4^+^ T-cells; 95% CI: 30 to 173.5). An increase in usRNA in resting CD4+-T-cells was observed in 17/20 patients, including all the 16 patients with NF-κB activation. During the intensification, a significant increase in CA-US RNA was detected (p=0.0145) (Fig.1). **Figure 1.**

Conclusions {#jve2_30-sec-0004}
===========

These results confirm our previous findings. Together, these data suggest MVC could increase the transcription of latent HIV-1, potentially by upregulation of the NF-kB pathway, in suppressed HIV-1-infected patients. MVC could be useful as part of a combination regimen of latency reactivating agents.

Acute and Early Infection

31 Systematic review of the current literature on structured treatment interruptions in HIV-infected patients receiving antiretroviral therapy -- implications for future HIV cure trials
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Background {#jve2_31-sec-0001}
==========

Structured treatment interruptions (STI) in patients on antiretroviral treatment (ART) for HIV-infection have been widely discussed, with development of viral resistance and increase of morbidity being of concern. However, current efforts for potential HIV cure strategies will require clinical trials that depend on analytical treatment interruptions (ATI) as an informative outcome parameter. We report on a systematic review of current evidence on STIs and propose potential strategies for safe ATI as part of clinical trials on HIV cure.

Methods {#jve2_31-sec-0002}
=======

A systematic literature search on studies reporting on STIs was conducted using a defined search term. Therefore, Web of Science Core Collection, Korean Journal Database, Medline, and SciELO, covering the period from 1945 to 12/2015 were considered. All interventional and observational studies were reviewed and results extracted based on predefined criteria.

Results {#jve2_31-sec-0003}
=======

We identified 847 potential studies investigating STI. 34 studies including 25,898 patients, mostly enrolled into randomized controlled trials (RCTs) or interventional trials, met the inclusion criteria. Sample sizes varied from nine to 5,472 patients among studies (median: 70.5). The duration of STI ranged from seven days to 49 months with overall follow-up durations varying from 24 weeks up to three years. Follow-up schedule varied from weekly to every two months. Patients experienced viral rebound (VL\>50 copies/ml) for up to 1,018 days after STI. Four large trials with a follow-up interval (up to six months) and 4,881 patients under STI reported the development of resistances in 18 patients. Adverse events and death were observed in 285 and 298 respectively. Disease progression to CDC stage B or C was reported in 548 patients. In comparison, ten small studies, with follow-up intervals (up to 30 days) and 527 patients in total, reported resistances in 17 patients and no adverse events or deaths were observed.

Conclusions {#jve2_31-sec-0004}
===========

While large RCTs demonstrated detrimental effects of STIs on the health of HIV-infected patients, most had long follow-up intervals of up to six months. Small studies with short follow-up intervals and early treatment re-initiation did not show an increase of adverse effects. ATI may be a feasible strategy as part of HIV cure trials if patients undergo intense follow-up routines.

Acute and Early Infection

32 Alarmin IL-33/ST2 pathway as an inductor of T-cell dependent response in acute and early HIV-infected patients
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Background {#jve2_32-sec-0001}
==========

IL-33 is an alarmin expressed in endothelial, epithelial and myeloid cells and has been shown to induce CTL response in LCMV mouse infection and its function is regulated by soluble receptor ST2 (sST2) which acts as a decoy receptor. sST2 which reflect IL-33-induced inflammation have been used as a biomarker in cardiovascular and autoimmune disorders. We assessed the association of plasma levels of IL-33 and sST2 on CD4 and CD8 T-cell expansion, activation/exhaustion in primary (PHI) and chronic HIV infection (CHI).

Methods {#jve2_32-sec-0002}
=======

132 HIV-infected patients and controls were analyzed (48 PHI and 84 CHI). We prospectively assessed 41 PHI and 20 CHI patients receiving or not ART. Plasma levels of IL-33, sST2, IL-6, IL-10, IFN-γ, I-FABP, sCD14 and sCD40L were measured by ELISA. Expression of markers of activation (HLADR/CD38) and exhaustion (PD-1) on CD4 and CD8 T-cells was assessed by FACS.

Results {#jve2_32-sec-0003}
=======

PHI vs. CHI presented with a lower viral load (4.28±1.08 vs 4.75±0.93; p=0.02), higher CD4 (544 vs. 331; p\<0.01), and a similar CD8 count (927 vs. 858). IL-33 levels were low in all groups. PHI patients presented higher sST2 than CHI and controls (18538, 15115 and 11067 pg/mL respectively; p\<0.01). No association of sST2 levels was observed with CD4 and viral load contrasting with a positive correlation with CD8 count (r=0.289; p=0.04) in PHI. Elevated sST2 levels positively correlated with HLADR-CD38 expressing CD4 (r=0.486; p\<0.01) and CD8 (r=0.362, p=0.02). However, correlation with elevated sST2 levels was observed only for PD-1 expressing CD4 (r=0.400; p=0.01) and not for CD8, likely due to their apoptosis during the immune contraction phase. Such associations were lost with treatment and during CHI. sST2 levels significantly correlated with IFN-γ and with markers of gut damage and microbial translocation (I-FABP, sCD14 and sCD40L) in PHI.

Conclusions {#jve2_32-sec-0004}
===========

Plasma sST2 level may reflect gut expression of IL-33 as its dynamics mirror CD8 expansion, activation/exhaustion and microbial translocation markers over the course of HIV infection.

Novel approaches in immunotherapeutics (including bnAbs and anti-inflammatory mediators)

33 A novel bispecific immunoadhesin displays enhanced breadth and potency against diverse HIV-1 subtypes
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Background {#jve2_33-sec-0001}
==========

Without an effective vaccine for eliciting broadly neutralizing antibodies (bnAbs), passive immunization using existing bnAbs, Ab-like immunoadhesins (IAs) or bi-specific bnAbs/IAs becomes an attractive strategy for human immunodeficiency virus (HIV) prevention and immunotherapy. We aimed to generate a bi-specific IA (BiIA) with improved breadth and potency against diverse HIV-1 subtypes.

Methods {#jve2_33-sec-0002}
=======

Based on the newly identified HIV-1 bNAbs, we have designed and constructed five secretory IAs (PG9, PG16, PGT128, hu5A8, VRC01) by linking the gene-optimized scFv of antibodies with the hinge and Fc regions of human IgG1. Bi-specific IAs were generated by either single gene encoded or "knobs into holes" methods. The breadth and potency of BiIAs were evaluated by a panel of 40 HIV-1 Env-pseudotyped viruses or three live viruses in vitro and their efficacy were assessed in humanized NSG mice.

Results {#jve2_33-sec-0003}
=======

We found that one single gene-encoded bi-specific IA (combining PGT128 and hu5A8), namely BiIA-SG, neutralized 100% of the 40 viruses tested, including five transmitted/founder viruses and two viruses resistant to both parental IAs. The mean IC50 (1.122 nM) of BiIA-SG is significant better than that of parental PGT128 (69.1 nM) and hu5A8 (13.0 nM). Moreover, BiIA-SG achieved complete protection against live HIV-1JFRL and Transmitted/Founder HIVBJZS7 challenges in humanize NSG mice. No infected cells were found in all tissue compartments tested including brain, spleen, lung, intestine, kidney and liver. Critically, AAV-delivered BiIA-SG also exhibited complete suppression of viral replication in HIV-1JFRL-infected animals. Interestingly, splenocytes derived from 2/5 treated mice did not cause new infections in new naïve humanized NSG mice via adoptive transfer experiments.

Conclusions {#jve2_33-sec-0004}
===========

Our results demonstrated that the novel BiIA-SG is an attractive candidate of passive immunization for antibody-based prophylactics and immunotherapy.

Novel approaches in immunotherapeutics (including bnAbs and anti-inflammatory mediators)

34 Novel conserved element HIV/SIV DNA vaccines maximize breadth and magnitude of immune response
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Background {#jve2_34-sec-0001}
==========

HIV sequence diversity and potential "decoy" epitopes are hurdles in the development of an effective AIDS vaccine. To target immune responses towards invariable viral regions, we engineered DNA-based immunogens encoding conserved elements (CE) of HIV-1 selected on the basis of stringent conservation, functional importance, broad HLA-coverage, and association with viral control.

Methods {#jve2_34-sec-0002}
=======

DNA vectors were generated expressing 7 collinearly arranged CE from p24^gag^ to cover \>98% of group M sequences. By analogy, a similar vaccine was developed against SIV Gag. Heterologous DNA regimens consisting of CE prime were followed by a boost with DNA expressing either full-length Gag or a combination of CE+full-length Gag. Immune responses were evaluated in macaques vaccinated by IM/electroporation.

Results {#jve2_34-sec-0003}
=======

All HIV and SIV CE DNA-vaccinated macaques developed robust CE-specific memory responses with a significant fraction of cytotoxic T cells. In contrast, vaccination with HIV or SIV full-length *gag* DNA was very inefficient in inducing CE responses (50% responders; fewer CE recognized). Subsequent *gag* DNA vaccination significantly boosted the preexisting CE responses. Interestingly, vaccination with a combination of CE+*gag* DNA efficiently increased the breadth of preexisting CE responses, indicating a significant change in epitope hierarchy both for the HIV and SIV vaccine regimens. The induced T cell responses rapidly disseminated into secondary lymphoid organs and effector mucosal sites. CE responses were maintained for \>2 years. A single booster vaccination with CE DNA resulted in rapid increase of pre-existing responses reaching up to \~7% of total T cells.

Conclusions {#jve2_34-sec-0004}
===========

Priming with CE DNA is critical to induce broad responses to vulnerable sites of the virus while avoiding variable or decoy targets that may divert effective T cell responses towards less protective viral determinants. Combination of CE and full-length immunogens provides a novel strategy to increase the breadth and magnitude of cellular and humoral immunity. This strategy allows for the development of robust T cell responses targeting a broad number of epitopes, including subdominant conserved viral epitopes. The expanded breadth of the responses could provide an advantage in restricting viral propagation. This vaccine regimen is currently under development for testing in an HVTN clinical trial.

Targeting HIV persistence during ART (cure strategies)

35 Therapy with the immunomodulatory agent pomalidomide does not lead to changes in HIV-1 viral populations in vivo
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Background {#jve2_35-sec-0001}
==========

HIV persistence in long-lived infected cells represents a barrier to viral eradication. Immune modulatory agents (IMiDs), including pomalidomide, have marked effects on T cell function, including increased CD4/CD8 proliferation (Polizzotto et al 2014). However, the impact of IMiDs on the HIV reservoir is unknown. We evaluated the effect of pomalidomide on HIV reservoirs by characterizing the size, structure and dynamics of HIV populations in individuals undergoing pomalidomide treatment.

Methods {#jve2_35-sec-0002}
=======

HIV-1 infected individuals (14 males, median age 49.5 y, median CD4=437 cells/μl), undergoing combination antiretroviral therapy with HIV RNA\<50 copies/ml, enrolled in an NCI trial (NCT01495598) of pomalidomide (5 mg/day for 21 days per 28 day cycle) for co-morbid Kaposi sarcoma were studied. PBMCs were obtained at study entry, following cycle 2, and at therapy completion (median 7 cycles). Levels of plasma RNA, peripheral blood mononuclear cell (PBMC) associated HIV DNA and RNA were determined (ddPCR, real time PCR), and HIV populations analyzed using single genome sequences obtained from the p6-RT region of PBMC-derived HIV DNA. Sequences were aligned (CLUSTALW), analyzed to characterize phylogenetic structure (MEGA), population shifts (geographic subdivision), and migration (Simmonds AI, Slatkin-Maddison in HyPhy).

Results {#jve2_35-sec-0003}
=======

Participants tolerated pomalidomide without complications. Levels of plasma RNA, PBMC-associated HIV DNA (CAD) and RNA (CAR) at study entry (range \<0.5- 58, median 1.5 RNA copies/ml; range 102--2072, median 779 CAD copies/million PBMC; range 220--1600, median 470 CAR copies/million PBMC) did not undergo significant change (p=0.16 RNA, p=0.29 CAD, p=0.53 CAR) after two cycles of pomalidomide or at study completion (p=0.25 RNA, p=0.53 CAD, p=0.27 CAR). HIV populations were genetically diverse at baseline (average pairwise difference, range 0.5--2.4 %) and included identical sequences. No evidence of expansion, population shift, or migration of any viral population was detected during or following pomalidomide therapy; some identical sequences persisted throughout study period. Minor changes in populations were detectable by pairwise difference analysis.

Conclusions {#jve2_35-sec-0004}
===========

Pomalidomide neither expanded nor reduced cell associated HIV populations. HIV clonal variants persisted during pomalidomide therapy, but clonal expansions were not detected. Our data suggests that the sole use of pomalidomide is not sufficient to alter the HIV reservoir and impact HIV persistence.
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36 Dose-dependent effects of HDACi on T cell activation and HIV latency reversal
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Background {#jve2_36-sec-0001}
==========

Histone deacetylase inhibitors (HDACi) can reverse HIV latency; however, immune-mediated killing of reactivated cells is inefficient. Contradictory results have been reported regarding negative effects of HDACi on immune responses, which may differ depending on the type of HDACi and doses used. To investigate this, we examined T cell activation and HIV reactivation in Jurkat cells at a range of HDACi doses. **Figure 36.1.** Representative graph of J-Lat reactivation and Jurkat NFAT signal at different HDACi (i.e. panobinostat) concentration

Methods {#jve2_36-sec-0002}
=======

Jurkat or J-Lat (clone 9.2) cells were transfected with an NFAT-luciferase reporter plasmid alone or in combination with an HIV Gag-specific TCR. Cells were treated with HDACi (i.e. panobinostat and romidepsin) for 24 h, followed by detection of HIV reactivation (% GFP+ cells) in J-Lats by flow cytometry or stimulation using PMA/ionomycin or co-culture with peptide-pulsed target cells for 6 h. NFAT signaling was measured by luminescence. Cell viability (Annexin-V/7-AAD), Gag-p24 expression, and intracellular cytokines (IL-2 and IFNγ) were measured by flow cytometry. TNFα was used as positive control for reactivation and negative control for activation.

Results {#jve2_36-sec-0003}
=======

Significant toxicity was observed with HDACi; a 50% cytotoxicity dose (CC50) was calculated. In Jurkats treated with HDACi at doses below or near the CC50 prior to stimulation with PMA/ionomycin, NFAT signaling was enhanced 15- to 25-fold and cytokine producing cells increased 14--31% (for IL-2) and \~5% (for IFNγ). Similar results were seen for J-Lats stimulated with PMA/ionomycin and Jurkats stimulated via TCR. In contrast, doses of HDACi above the CC50 were required to reactivate HIV in J-Lats.

Conclusions {#jve2_36-sec-0004}
===========

Results suggest that distinct mechanisms contribute to the ability of HDACi to stimulate gene expression versus activity to reverse latency. HDACi doses below the CC50 enhanced measures of T cell activation, while doses above the CC50 were necessary to reactivate HIV. The concentration of HDACi used for studies must balance immune stimulation and toxicity with viral reactivation efficiency to enhance shock and kill strategies.
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37 Novel pathways of Tat expression identify new targets for reactivation of latent HIV-1
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Background {#jve2_37-sec-0001}
==========

HIV-1 remains incurable due to the persistence of cells that harbour replication-competent virus in a non-productive state of infection. In this study, we characterised the expression of the HIV-1 Tat protein through a novel internal ribosome entry site (IRES) and explored its significance for reactivation of latent HIV. We examined the structure of chimeric cellular:HIV products in latently infected primary cells and assessed the properties of Tat translation from an IRES element within chimeric cell:*tat* readthrough transcripts.

Methods {#jve2_37-sec-0002}
=======

HIV-containing RNAs were enriched from the CCL19-chemokine induced primary cell model of HIV-1 latency, as well as latently infected patient cells. Chimeric cellular:HIV RNAs were identified by RNA-Seq using llumina Mi-Seq. The Tat coding potential of these was investigated using expression plasmids and derivative lentivectors that contain either the HIV-1~NL4.3~ Tat-86 coding exons in a conventional cap-dependent mRNA translation context, or in an unfavorable chimeric human growth hormone:*tat*mRNA context where Tat exons were embedded in the hGH gene, requiring Tat to be translated from an IRES underlying *tat*-coding RNA. The ability of both native and chimeric Tat-encoding RNA to reactivate latent virus was assessed by lentivector transduction of the latently infected T cell line, J-Lat10.6.

Results {#jve2_37-sec-0003}
=======

In the CCL19-induced model of HIV-1 latency, chimeric messages represented \~0.2% of the RNA-Seq reads that were HIV sequences, and within these, several species of cellular:*tat*mRNA were detected. We showed that these are capable of Tat translation through the IRES element but with 6-fold lower efficiency than cap-dependent translation of Tat. The relative efficiency of Tat expression from the IRES was significantly increased during oxidative stress. HIV was also modestly increased in J-Lat10.6 cells after transduction with hGH-Tat lentivectors.

Conclusions {#jve2_37-sec-0004}
===========

Primary T-cells latently infected with HIV contain cell:*tat* chimeric RNA that can translate HIV-1 Tat protein at low efficiency using an IRES element underlying coding exon 1. Tat expression from these mRNAs may be sufficient to weakly reactivate HIV from latency. Pharmacological approaches that increase the production of chimeric mRNA or Tat translation through its IRES may foster specific reactivation of latent HIV-1.
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38 Small molecule inhibitors of BAF; a new family of compounds in HIV-1 latency reversal
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Background {#jve2_38-sec-0001}
==========

New pharmaceutical strategies aimed at HIV-1 eradication have focused on molecules able to induce HIV replication from latently infected cells in order to render them susceptible to immune clearance. We investigated the activity of a new class of latency reversal compounds targeting BAF chromatin remodeling complex, a key player required for establishment and maintenance of HIV-1 latency and thus a promising molecular target for HIV-1 latency reversal.

Methods {#jve2_38-sec-0002}
=======

Activation of latent HIV-1 following treatment with BAF inhibitors (BAFi\'s) was determined in cell line models of latency. Active compounds were further characterized at the molecular level by Western Blot, chromatin immunoprecipitation and FAIRE assays. Furthermore, cells were treated with BAFi\'s in combination with Prostratin and SAHA to determine whether BAFi\'s synergistically interact with known latency reversal agents (LRAs). Finally BAFi\'s activity was confirmed in primary models of latency and in cells obtained from virally suppressed HIV-1 infected patients.

Results {#jve2_38-sec-0003}
=======

Latency reversal was strongly induced by 2 of the BAFi\'s included in the initial screening: Caffeic Acid Phenethyl Ester (CAPE) and Pyrimethamine (PYR). BAFi\'s reversed HIV-1 latency in cell line based latency models, in two ex vivo infected primary cell models of latency as well as in HIV-1 infected patient\'s CD4+ T cells, without inducing T cell proliferation or activation. Consistent with the observed latency reversal activity, treatment with BAFi\'s resulted in displacement of BAF complex from HIV-1 LTR as well as nucleosome remodeling in HIV-1 promotor region. Moreover, BAFi-induced HIV-1 latency reversal was synergistically enhanced upon treatment with the PKC pathway activator Prostratin and the HDAC inhibitor SAHA.

Conclusions {#jve2_38-sec-0004}
===========

Molecules targeting the BAF complex reverse HIV-1 latency. For their activity in primary CD4+T cells and the synergistic interaction with known LRAs, BAFi\'s represent a promising family of molecules for inclusion in HIV-1 latency reversal regimens.

Targeting HIV persistence during ART (cure strategies)

39 Novel activators and suppressors of latent HIV-1 from natural products
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Background {#jve2_39-sec-0001}
==========

Combination antiretroviral therapy (cART) durably suppresses HIV replication, but virus persists in cellular reservoirs. Latency reversal agents (LRAs) capable of reactivating HIV-infected cells may promote their elimination through host or viral cytopathic effects; an approach termed "shock-and-kill". However, current LRAs have shown limited clinical success, and no single LRA reactivates all latent cells. Conversely, "deep-latency" agents (DLAs) that promote long-term suppression of viral transcription that is refractory to subsequent reactivation are few in number and not yet assessed *in vivo*. Thus additional LRAs and DLAs are needed.

Methods {#jve2_39-sec-0002}
=======

We examined 433 pure compounds from marine natural products and medicinal plants using J-Lat 8.4 GFP-reporter T cells containing an NL4.3Δenv/nef genome. Compounds that induced GFP in \>5% of cells while retaining \>30% cell viability at 5 μg/mL were assessed for synergism with established LRAs. Compounds that blocked \>50% GFP expression induced by 50 ng/mL TNFα were assessed for antagonism of LRAs and ability to block a doxycycline-induced, Tat/TAR-deficient provirus. Select compounds were also tested in infected, primary resting CD4 T-cells using the Tat/Rev-Induced Limiting Dilution Assay (TILDA).

Results {#jve2_39-sec-0003}
=======

We identified 8 new LRAs and 2 DLAs. Two novel phorbol esters induced GFP in 6.0 ± 0.6 and 6.9 ± 0.4% of cells at 0.03 μg/mL, respectively, having \~10-fold less activity than PMA but \~100-fold greater than prostratin. Interestingly, these compounds originate from a plant used by African traditional healers to treat AIDS symptoms. Anthrone "p61" reactivated 9.9 ± 0.9% of cells at 5 μg/mL and synergized with panobinostat (HDAC inhibitor), prostratin (PKC activator), and TNFα, suggesting a distinct mechanism of action. p61-containing plants are traditionally used to treat malaria, and p61 does not synergize with the anti-malarial artemisinin, suggesting related modes of targeting latent HIV. Two novel flavonoids at 5 μg/mL suppressed \>85% of GFP induction by TNFα, control LRAs, and production of Tat/TAR-deficient provirus, suggesting mechanism(s) distinct from previously-reported DLAs. Finally, both phorbol esters induced multiply-spliced vRNA expression in resting CD4 T-cells, while one flavonoid suppressed \>80% of PMA/ionomycin-induced vRNA.

Conclusions {#jve2_39-sec-0004}
===========

We identified potential new LRAs and DLAs of natural origin, including some supported by traditional medicine, that display synergy with established LRAs and/or distinct mechanisms of action.

Targeting HIV persistence during ART (cure strategies)

40 A systems dynamics approach to identifying novel HIV treatments
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Background {#jve2_40-sec-0001}
==========

A functional cure for HIV remains elusive because of the complex interactions between HIV and the immune system. System dynamics, a proven computer simulation methodology derived from engineering control theory, deals with the behavior of complex feedback systems and has potential application in predicting therapeutic combinations for HIV treatment.

Methods {#jve2_40-sec-0002}
=======

We developed a systemic mathematical model of HIV infection from the initial infection site to the immune system, including antigen-presenting cells, lymphocytes and secondary lymphoid organs. We assessed the dynamic interactions between HIV and the immune system based on an intensive literature review and collaboration with leading HIV researchers

Results {#jve2_40-sec-0003}
=======

The mathematical model reproduced key disease characteristics including the viral load and the CD4^+^ T cell decline as HIV progresses from acute to established infection in untreated subjects. Plasma viral load remains undetectable for 1 to 2 weeks following HIV exposure then rises rapidly to approximately 7 log~10~ RNA copies/mL and drops rapidly by 2 log~10~ at week 3 following infection (Figure 1). Ten weeks later, a long-term set point of around 4 log~10~ RNA copies/mL is established. CD4^+^ T cell counts decline by 50% from a pre-infection value of just under 1000 cells/μL during the time-frame that viral load peaks. T cell count then recovers to just over 750 cells/μL before a long-term decline of 50 to 75 cells/μL per year (Figure 40.1). We validated the model via simulating HIV treatment options from a range of published trials including mono and combination therapies. **Figure 40.1.** Simulated Viral Load and CD4+ T counts

Conclusions {#jve2_40-sec-0004}
===========

The immune system model platform provides the opportunity for *in silico* hypothesis testing to better understand immune system physiology, incorporate new insights from ongoing clinical studies, and explore novel combination therapies in a broader and more time-efficient manner compared to the traditional preclinical pathway

Targeting HIV persistence during ART (cure strategies)

41 Vitamin D level in cART treated patients is critical for HIV reservoir size
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Background {#jve2_41-sec-0001}
==========

In HIV-infected patients Vitamin D (25-hydroxycholcalciferol) deficit plays a role by its immunomodulatory functions and participate to increase systemic immune activation. Moreover it has been associated with disease progression.

The objective of this work was to explore the association of vitamin D and immuno-virological and therapeutics factors to HIV-reservoir level measured by total HIV-DNA quantification.

Methods {#jve2_41-sec-0002}
=======

HIV-1 infected men \<50 years, presenting an HIV-RNA \<50 copies/ml since \>6 months with antiretroviral treatment (cART), were enrolled in a prospective study. At inclusion, HIV-RNA, HIV-DNA in PBMC (Biocentric, Bandol, France), TCD4, TCD8 counts and vitamin D (ECL Roche) were quantified and zeniths HIV-RNA, nadir of CD4, therapeutic history were collected. A logistic multivariate regression model was used for statistical analysis.

Results {#jve2_41-sec-0003}
=======

207 men were recruited between 2013 to 2015 from Bicêtre Hospital AP-HP and Tourcoing Hospital (France). At inclusion, median age was 43 years, HIV-DNA: 2.97 log~10~ copies/10^6^ PBMC \[IQR: 2.18--3.23\], and vitamin D level: 29 μg/l \[21--36\]. Zenith of HIV-RNA was 4.97 log~10~ copies/ml \[2.49--5.38\] and nadir CD4 count 278 \[215--382\]. In multivariate analysis, factors associated with HIV-DNA \<2.97 log~10~ were: the vitamin D level more than 30 μg/L \[RCa=0.36, 95% CI 0.14--0.90; p=0.03\] and zenith of HIV-RNA \<5 log~10~ \[RCa=0.22, 95% CI 0.08--0.62; p\<0.01\]. Combined-ART regimen containing nucleoside analog reverse-transcriptase inhibitors more than 46 months \[RCa=0.40, 95% CI 0.16--1.0; p=0.05\] was also associated with a lower level of blood HIV-DNA.

Conclusions {#jve2_41-sec-0004}
===========

Our results show that vitamin D deficiency participates to the reservoir maintenance probably by favoring immune-activation. They also strengthen the role of Vitamin D level in HIV-pathogenesis. These results should be considered for the design of novel trials aiming to decrease HIV-reservoirs in the HIV Cure agenda.

Therapeutic Vaccines

42 Characterization of monocyte-derived dendritic cells used in immunotherapy for HIV-1-infected individuals
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Background {#jve2_42-sec-0001}
==========

Therapeutic vaccine, based on Monocyte-Derived Dendritic Cells (MDDCs) has been shown to be a promising strategy for the treatment of HIV-infected individuals. A clinical trial based on MDDCs for chronically HIV-infected untreated individuals is currently underway in our laboratory. This clinical trial offers an opportunity to correlate phenotypic and functional aspects of MDDCs with the response to the immunotherapy *in vivo*.

Methods {#jve2_42-sec-0002}
=======

From 2011--2014, 19 HIV-infected individuals were immunized in Sao Paulo,Brazil. Peripheral blood mononuclear cells (PBMCs) were obtained by leukapheresis. Autologous virus was obtained by culturing PHA-stimulated CD4^+^ T enriched PBMCs and was inactivated with Aldrithiol-2 (HIV-AT-2). Monocytes were obtained by plastic adherence and were differentiated into DCs in the presence of IL-4 and GM-CSF. At day 5, they were pulsed with HIV-AT-2 and stimulated with TNF-α, IL-6 and IL-1β. The study had three groups, each one received 3 doses of vaccine. Group 1 (n=4) received non-pulsed 3×10^7^ mature; Group 2 (n=9) received 3×10^6^ HIV-AT-2 pulsed and Group 3 (n=6) received 3×10^7^ HIV-AT-2 pulsed MDDCs. For phenotypic analysis flow cytometry was performed. For the functional characterization endocytosis, as uptake of FITC-dextran, and co-cultivation, with autologous lymphocytes, were performed.

Results {#jve2_42-sec-0003}
=======

After pulsing MDDCs there was an increased expression of MHC class II (mean 85,4%); the activation molecule CD83 (84,6%); costimulatory molecules CD80 (80,5%) and CD86 (90,4%), and chemokine receptors CCR5, CXCR4 and CCR6, showing mature MDDCs profile. Regarding phagocytosis, around 30% of immature MDDCs were able to internalize FITC-dextran. Besides this, mature MDDCs were able to induce antigen-specific responses in 3% of autologous CD4+ and 1% of CD8+T lymphocytes producing cytokines. Finally, mature MDDCs were found to be potent enough to stimulate the proliferation of 5% of autologous lymphocytes.

Conclusions {#jve2_42-sec-0004}
===========

Effective induction of cell-mediated immune responses strongly depends on the ability of DCs to migrate to lymph node, prime T-Cells and consequently produce Th1-polarizing cytokines. Collectively, the results obtained so far show that MDDCs used in the vaccine have the potential to promote some level of immunogenicity in vaccinated patients.

Therapeutic Vaccines

43 siRNA based TLR7/8 activation, MHC class I recycling from endosome and cross presentation of HIV-1 antigen for elevated CD8+ response: an approach for intracellular vaccine
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Background {#jve2_43-sec-0001}
==========

During chronic HIV-1 infection, INF-1 molecule production decreases upon induction of IFN regulatory factor 1 (IRF-1). On the other hand, HIV-1 *Nef* mediated Major Histocompability Complex 1 (MHC-1) down regulation is common in HIV-1 infection hence severely limiting the endogenous antigen presentation. Here we report a synthetic siRNA-fusion peptide complex that uplifts the INF-I production via TLR7/8 activation and also inhibits MHC class I (MHC-I) down regulation, using *Tick*-*borne encephalitis virus*soluble Envelope (TBEVsE) as fusogenic peptide, in HIV-1 infected T cells in vitro, thus mitigating the viral replication.

Methods {#jve2_43-sec-0002}
=======

Co transfection of 293FT cells with ViraPower™ Packaging Mix (pLP1, pLP2, pLP/VSVG) and pLenti expression vector containing MHC class I.TBEVsE.ShRNA.MS-2-p19~MHC-I~ (~LT~MHC) yielded the lentiviral titre. The control eYFP (enhanced yellow florescence protein) expressing vectors were constructed in similar manner. For the titration of lentiviral stock, the supernatant was harvested from 293FT after 24 hours using 0.22 μm sterile filter. After viral vector construction for ~LT~MHC delivery and intregation as proDNA in Nef+/Nef- expressing Th cell*,*pulse chase assay was done to report the trafficking of HLA-A2 in presence or absence of ~LT~MHC in Nef+/Nef- Th cell. Measurement of HLA-A2 transport Rate by pulse chase assay was done with endo H digestion. IFN I production was evaluated on the basis of ELISA. To quantitate viremia, real-time RT-PCR was performed to measure the number of copies of viral RNA.

Results {#jve2_43-sec-0003}
=======

Here we report recycling of MHC-I molecule, with endogenous HIV-1 antigen attached, from late endosome (pH 6.5) with the help of chimeric ~LT~MHC, with fusion peptide TBEVsE, which facilitated the escape of MHC-I from late endosome thus enabling the molecule to resume the surface expression pathway. TBEVsE complex salvaged heavy chain-β~2~m heterodimer along with intact HIV-1 antigen. siRNA coupled with p19 protein assisted in activating TLR 7/8 which were confirmed by the increment of INFβ molecules (P\<0.001) in Nef+/Nef- Th cells.

Conclusions {#jve2_43-sec-0004}
===========

This study indicates that there are in fact possibilities for intracellular vaccine mechanism which can harness innate as well humoral immune system against infection thus may have potential as a therapy against HIV.

Therapeutic Vaccines

44 Volunteer motivators for participating in HIV vaccine clinical trials in Nairobi, Kenya
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Background {#jve2_44-sec-0001}
==========

1.6 million Kenyans are living with HIV/AIDS as per 2014 estimates. There is a notable decline in new HIV infections however efforts are still needed to develop an efficacious, accessible and affordable HIV Vaccine. Clinical trials involve the active participation of volunteers and may involve a prolonged period of follow up of up to one year. HIV clinical vaccine trials involve risks and are a first in humans hence a need to understand volunteer motivators for enrollment, retention and follow-up. Health belief model classifies motivators into social benefits such as 'advancing research' and Collaboration with Science and personal benefits such as health benefits and financial interests.

Methods {#jve2_44-sec-0002}
=======

A systematic review was carried out on data obtained from four (4) HIV clinical vaccine trials conducted at KAVI-Institute of Clinical Research in Nairobi, Kenya from 2011--2015. Responses were obtained from the General Questionnaire applied to the volunteers during their screening visit at the research site.

Results {#jve2_44-sec-0003}
=======

A total of 281 volunteers participated in the 4 HIV vaccine trials used in this study. These were healthy, HIV-uninfected individuals. A general questionnaire applied to the volunteers revealed that, 38% (n=108) were motivated by personal benefits, out of these 81% (n=88) were motivated by health benefits and 19% (n=20) by the possibility of financial gains. In addition, 62% (n=173) of the volunteers were motivated by social benefits with 32% (n=55) of these seeking to help their family/society/world while 68% (n=118) were interested in advancing research.

Conclusions {#jve2_44-sec-0004}
===========

Despite HIV combination prevention tools (condoms, VCT, TaSP) over 100,000 new HIV infections were reported in 2012. Education on what is needed (including volunteer participation) to develop an efficacious vaccine could be the key to greater volunteer motivation to participate in clinical trials. Awareness and understanding of factors that motivate volunteers to participate in a clinical trial can help to strategize and refine targeting of volunteers in future HIV vaccine clinical trials.

Therapeutic Vaccines

45 HIV-tat fused to the oligomerisation domain of the c4-binding protein is highly immunogenic and controls EcoHIV challenge in mice
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Background {#jve2_45-sec-0001}
==========

The HIV Tat protein is a promising component of a HIV vaccine. A DNA-based Tat vaccine would be a cheap, cost-effective and therefore readily accessible HIV-1 vaccine to low-income communities which are greatly affected by HIV. However, native Tat is highly unstable, easily oxidised and degraded by proteolysis, which affects its immunogenicity. Thus, protecting Tat from these detrimental processes would be expected to improve Tat immunogenicity.

Methods {#jve2_45-sec-0002}
=======

We have developed a candidate Tat-DNA vaccine (pVAX-sTat-IMX313) encoding Tat fused with the oligomerisation domain of a chimeric C4-binding protein (C4b-p), termed IMX313, resulting in Tat heptamerisation. To ensure that the bulk of heptamerised Tat is secreted, we linked Tat to the leader sequence of tissue plasminogen activator (TPA). Another DNA vaccine (pVAX-sTat) encoding Tat linked to TPA, but without IMX313 was also developed as a control. Balb/c mice (n=7 per group) were vaccinated intradermally with 5 doses (50 μg/dose) of pVAX-sTat-IMX313 or pVAX-sTat. Splenocytes were harvested 14 days after the last dose and analysed for Tat-specific cell-mediated immunity by ELIspot. Blood and cervical vaginal lavage samples were harvested prior to each dose and 14 days after the last dose and analysed for Tat-specific serum (IgG) and mucosal (IgA), respectively.

Results {#jve2_45-sec-0003}
=======

Peptide-stimulated splenocytes from pVAX-sTat-IMX313 vaccinated mice showed higher Tat-specific IFN-γ responses than pVAX-sTat vaccinated mice (mean SFUs 601 vs 498). pVAX-sTat-IMX313 vaccinated mice developed higher titres of IgG (\~1: 65957 vs 35871) that showed higher inhibition of Tat transactivation activity in an *in vitro* assay (\~80% vs 76% inhibition). IgA was detected in 7/7 (100%) of pVAX-sTat-IMX313- and in only 4/7 (57%) pVAX-sTat-vaccinated mice. The EcoHIV viral load (a surrogate murine HIV challenge model) was reduced by \~11 fold in the peritoneal cavity (*p*=0.0022) and by \~7 fold in the spleen (*p*=*0.*0022) in pVAX-sTat-IMX313- compared with pVAX-sTat-vaccinated mice.

Conclusions {#jve2_45-sec-0004}
===========

We believe that this is the first time secreted Tat has been fused to IMX313 to improve the immunogenicity of Tat-DNA vaccine and highlights the need to further test pVAX-sTat-IMX313 in large animals and humans.

Novel Animal/Virus Models for Vaccine, Cure Research, and Inhibitor Development

46LB A nonhuman primate model of fully MHC-matched allogeneic stem cell transplantation to study HIV reservoir clearance
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Background {#jve2_46-sec-0001}
==========

Timothy Brown remains in full HIV remission following an allogeneic hematopoietic stem cell transplant (HSCT). Three potential reservoir-clearing mechanisms exist which may explain this remission: 1) myeloablative immune-conditioning chemotherapy 2) graft-versus-host immunity, or 3) the *ccr5^Δ32/Δ32^* stem cell graft. Attempts to repeat Mr. Brown\'s HSCT-mediated cure in the clinic have failed, necessitating a clinically relevant animal model to understand the mechanisms of his cure. The complex immunogenetics of rhesus macaques (*Macaca mulatta*) precludes their use as a fully MHC-matched HSCT model. Here, we present a nonhuman primate model of fully MHC-matched allogeneic HSCT to define the mechanisms of Timothy Brown\'s functional HIV cure.

Methods {#jve2_46-sec-0002}
=======

Fully MHC-matched Mauritian cynomolgus macaques (MCM -- *Macaca fascicularis*) donor-recipient pairs were used to perform HSCT. Mobilized peripheral stem cells were collected from donors by leukopheresis and transplanted into recipients following chemotherapy and total body irradiation. Donor engraftment was monitored by Illumina deep sequencing across 12 single nucleotide polymorphisms to distinguish donor cells. Immune subset reconstitution was assessed longitudinally using multiple flow cytometric phenotyping panels.

Results {#jve2_46-sec-0003}
=======

We performed seven HSCT between MCM with four distinct outcomes (listed in chronological order): 1) engraftment failure (N=1), 2) graft rejection (N=2), 3) lethal acute GVHD (N=2), and 4) long-term stable chimerism (N=2). We observed strong engraftment in all immune subsets, including T cells, in our long-term stable chimeras. Importantly, with our improved GVHD prophylaxis we have observed no evidence of pathologic acute GVHD despite full donor engraftment for over 100 days.

Conclusions {#jve2_46-sec-0004}
===========

We have built a physiologically relevant model of fully MHC-matched allogeneic HSCT to elucidate the mechanisms contributing to the full HIV remission seen in Timothy Brown. We have achieved high frequencies of CD3+ T cell donor chimerism using this model, which will be a crucial component of any studies looking at SIV reservoir clearance. We are generating CCR5-null transgenic MCM for use as donors, and allogeneic HSCT are now underway in fully combination antiretroviral therapy-suppressed MCM.

Animal Models of Latency Reservoirs and Eradication

47 Immuno-PET/CT imaging reveals differences in virus and CD4+ cell localization in SIV infected rhesus macaques treated with an anti-α4β7 mab
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Background {#jve2_47-sec-0001}
==========

Integrin α4β7 mediates the trafficking of leukocytes including CD4^+^ T cells to lymphoid tissues in the gut, which are principal sites of HIV and SIV replication during acute infection.

Methods {#jve2_47-sec-0002}
=======

We evaluated the impact of an anti-integrin α4β7 mAb, which acts as an α4β7 antagonist, on the distribution of both SIV infected cells and CD4^+^ cells in rhesus macaques infected with highly pathogenic SIV on live animals using a PET/CT imaging technique. Probes for both the gp120 envelope protein and the CD4 receptor were employed.

Results {#jve2_47-sec-0003}
=======

We determined that the anti α4β7 mAb reduces viral replication in gut associated lymphoid tissues, but also in other tissues including lung, spleen and axillary and inguinal lymph nodes that are not linked to α4β7 mediated homing. The reduction in viral replication in gut tissues occurred despite the fact that α4β7 mAb treatment did not deplete gut tissues of CD4^+^ cells. Treatment with anti α4β7 during the acute phase of infection appeared to facilitate CD4^+^ cell reconstitution at a later stage of infection.

Conclusions {#jve2_47-sec-0004}
===========

These results demonstrate that an α4β7 antagonist can reduce viral replication in gut tissues without depleting those tissues of CD4^+^ cells. Because damage to the gut is believed to play a central role HIV pathogenesis, these results support further evaluation of α4β7 antagonists in the study and treatment of HIV disease.

Acute and Early Infection

48 Faster restoration of CD4:CD8 ratio during the first 12 weeks of ART initiated at early HIV infection compared with ART initiated at chronic infection in the same patients
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Background {#jve2_48-sec-0001}
==========

Early initiation of antiretroviral therapy (ART) is believed to result in better immunological reconstitution than initiation of ART during chronic HIV infection (CHI). However, the degree and rate of immune restoration haven\'t been directly compared in the same patients between ART initiated during primary HIV infection (PHI) and CHI ART.

Methods {#jve2_48-sec-0002}
=======

We studied 48 patients that received 24 or 60 weeks of temporary ART initiated at PHI and subsequently reinitiated ART during CHI after a median of 2.4 years without treatment. Clinical parameters were measured at ART initiation and every 12 weeks thereafter up to week 60 of both PHI and CHI ART.

Results {#jve2_48-sec-0003}
=======

Median CD4^+^ counts were 505 (IQR: 303--713) and 310 (245--418) cells/mm^3^ at the PHI and CHI ART baselines, respectively (p\<0.0001, paired Wilcoxon test). No difference in the dynamics of CD4^+^ count reconstitution between the PHI and CHI ART was observed throughout the follow-up period. Median CD4^+^ count gains by 60 weeks ART were 210 cells/mm^3^ for both PHI and CHI ART. In contrast, although there was no significant difference in the CD4:CD8 ratio at the PHI and CHI ART baselines (0.48 (0.25--0.80) vs. 0.36 (0.25--0.41), respectively; p\>0.05), by 12 weeks ART this ratio increased to 0.95 (0.74--1.29) on PHI ART and 0.52 (0.41--0.74) on CHI ART (p\<0.0001). Significant difference in CD4:CD8 ratio between PHI and CHI ART persisted throughout the follow-up period, but no further difference in the dynamics of CD4:CD8 ratio increase was observed after the first 12 weeks. By 48 weeks ART, 59% of patients treated during PHI and 24% of patients treated during CHI achieved the CD4:CD8 ratio of 1 (p=0.0049, Fisher′s test).

Conclusions {#jve2_48-sec-0004}
===========

This is the first study to directly compare immune reconstitution between PHI and CHI ART in the same patients. Although no difference was observed in the dynamics of CD4^+^ count reconstitution, the CD4:CD8 ratio demonstrated faster restoration in the first 12 weeks of PHI ART compared to the CHI ART, which translated into a larger percentage of patients achieving the CD4:CD8 ratio of 1 by 48 weeks ART. Early initiation of ART conveys a significant immunological benefit to the patient.

Acute and Early Infection

49 Using ddPCR to assess persistence of HIV DNA reservoirs in perinatally infected infants treated with cART before or after 12 months of age
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Background {#jve2_49-sec-0001}
==========

The major barrier to achieving HIV remission is the establishment of HIV in latent CD4+ T cells during acute infection. Recent studies suggest that early treatment of neonatal infection may reduce the establishment and quantity of latent reservoirs and enhance proviral decay, allowing potential drug-free HIV remission as seen in the "Mississippi baby." Data is limited, so we measured persistent HIV viral reservoirs and HIV antibody profiles in a cohort of 10 perinatally infected infants with known timing of treatment and serially banked blood samples.

Methods {#jve2_49-sec-0002}
=======

In a retrospective study, 10 HIV perinatally infected infants followed from birth and initiating cART before or ≥12 months of age were divided into "early" or "late" treatment cohorts. All children remained on cART. Serial analysis of banked peripheral blood samples were assessed for HIV RNA viremia, HIV antibodies, and proviral reservoirs over time. We measured HIV RNA PCR \~ Q4 months. Of those treated early, HIV antibody levels were assessed by 4th generation Western blot (WB) at 16 months and 1--5 years post-cART. We defined incomplete WB by band analysis (\<4 of 9 +). HIV DNA reservoirs were quantified by droplet digital PCR (ddPCR) at the same time points.

Results {#jve2_49-sec-0003}
=======

Of infants treated early, 5/8 (62.5%) had incomplete WBs at 16 months of age; 6/8 (75%) remained incomplete at second time point. Half of early treated with incomplete WBs, also had marked decrease in HIV provirus. ddPCR was performed in 10 infants, 8 with early Rx and 2 with late Rx. At 16 months of age the early Rx cohort had a mean proviral DNA of 12,773 copies/million cells compared to 14,864 copies/million cells at 1--5 years later.

Conclusions {#jve2_49-sec-0004}
===========

Preliminary data suggests that the majority of early treated infants showed incomplete antibody profiles by WB at 16 months which persisted in follow up. The quantity of proviral reservoir was not significantly different among the early cohort. However, a subset showed a decrease in proviral reservoir size. This data confirms that early treatment may inhibit viral replication and development of HIV antibody. Further studies are needed to correlate HIV antibody profiles with proviral reservoir levels.

Research reported in this publication was supported by the James B. Pendleton Charitable Trust.
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Background {#jve2_50-sec-0001}
==========

Strategies to reactivate the HIV reservoir and analytic treatment interruption (ATI) could each have adverse consequences on the central nervous system (CNS) through induction of neuroinflammation or viral escape. We performed a CNS study in parallel with a systemic study of vorinostat/hydroxychloroquine/maraviroc (VHM) followed by ATI.

Methods {#jve2_50-sec-0002}
=======

Acutely treated participants with \>48 weeks viral suppression and CD4 ≥450 cells/mm^3^ were randomized to 10 weeks of oral VHM (400 mg/day hydroxychloroquine + 1200 mg/day maraviroc + three 14 day cycles on and off of 400 mg/day vorinostat) + ART vs. ART, followed by ATI after wk10 with ART resumption at plasma VL\>1,000 copies/ml. CNS measures included cerebrospinal fluid (CSF) sampling at baseline prior to intervention, at wk10, and during ATI at first plasma VL\>20 copies/ml; neuropsychological testing at baseline, wk10, during ATI, and after resuming ART; and 3T brain magnetic resonance spectroscopy(MRS) at baseline and 6--8 weeks after ART resumption.

Results {#jve2_50-sec-0003}
=======

Ten participants who had started ART in Fiebig III/IV enrolled (VHM+ART=8, ART=2, 8 men, median age 30 and ART duration 4 years); one withdrew due to adverse VHM effects. In all participants, CSF VLs were \<20 copies/ml at baseline and wk10. Two VHM participants had detectable CSF VL (25 and 42 copies/ml) at plasma rebound (corresponding plasma 35,796 and 329 copies/ml) 3--4 weeks after ATI. CSF protein, a blood-brain-barrier disruption biomarker, rose above the upper limit of normal (45 mg/dL) in one participant during VHM (baseline: 34 mg/dL, wk10: 52 mg/dL, after ATI: 33 mg/dL). IP-10/CXCL10, a lymphocyte chemokine, rose in CSF after ATI (p=0.017). Global neuropsychological performance improved with repeated testing in all but one VHM participant whose z scores declined from −0.53 at baseline to −1.04 at wk10. Brain MRS in 6 participants at baseline and after ART resumption revealed no significant changes in neuronal or inflammatory measures.

Conclusions {#jve2_50-sec-0004}
===========

VHM, a latency reactivating intervention, did not lead to detectable CSF HIV RNA by standard assays nor evidence of persistent adverse outcomes based on CSF protein, neuropsychological testing performance, and brain MRS. Monitored ATI was associated with CNS immune activation; CSF HIV rebound occurred in 2 participants, at levels lower than in blood.

Ethical Issues in Clinical Trials and Treatment Strategies

51 HIV patients and caregivers viewpoints towards participation to future HIV cure-related clinical trials -- results from the second part of the French ANRS-APSEC survey
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Background {#jve2_51-sec-0001}
==========

The IAS "Towards an HIV cure" initiative promotes multidisciplinary research for a safe, affordable and scalable cure. The main goal of the ANRS-APSEC survey, forming part of this initiative, was to collect data based on stakeholders' viewpoints about HIV Cure-related clinical trials (HCRCT) that raised both hope and ethical questions. The present part of the survey was dedicated to elicit the main shared viewpoints of patients towards participation and caregivers towards proposition of HCRCT to their patients.

Methods {#jve2_51-sec-0002}
=======

The Q-methodology, combining qualitative and quantitative approaches, was designed to explore subjectivity and viewpoints. Thirty-three statements were defined to illustrate the dimensions pointed out by the 1^st^ step of the survey: treatments and follow-up; risks; benefits; patient-physician relationship; beliefs and attitudes; information; target population. 41 patients (ART-treated, virologically suppressed) and 41 caregivers, from 5 French HIV services were asked to rank-order the statements, from the ones they disagree the most with to the ones they agree the most with. A factorial analysis was used to identify the structure of the different viewpoints.

Results {#jve2_51-sec-0003}
=======

Patients and caregivers' consensus was expressed about the need to go on further with HIV research and with the referent HIV physician\'s confidence in HCRCT. Four distinct viewpoints were elicited for each group drawing a gradient of acceptability of HCRCT. For the 1^st^ viewpoint the motivation to participate/propose was mainly conditioned by fear of side effects (higher refusal among caregivers) and was particularly concerned with the targeted recruitment strategy for HCRCT (agreed by caregivers, refused by patients). The 2^nd^ viewpoint expressed the highest acceptation of risks and constraints and emphasized the need of information about HCRCT results. The 3^rd^ viewpoint was benefits-centred (with a broad refusal of side effects for patients) and was concerned with priority to be given to research HIV prevention and access to ART for all (elected by caregivers, refused by patients). The 4^th^ viewpoints clearly expressed reluctance towards HCRCT.

Conclusions {#jve2_51-sec-0004}
===========

Results showed the complexity of the motivations and the entanglement between the dimensions involved. They confirmed the importance of HCRCT design, management and communication for a good acceptance by patients and also by caregivers.

Ethical Issues in Clinical Trials and Treatment Strategies

52 How to keep high-risk early-phase HIV cure and long-term remission studies ethical: classifying candidate solutions
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Background {#jve2_52-sec-0001}
==========

According to [ClinicalTrials.gov](ClinicalTrials.gov), work toward a cure and long-term sustainable remission of HIV is currently the focus of 19 completed studies and at least 35 ongoing or planned ones. A central ethical challenge surrounds the benefit/risk ratio in some of these studies. Many would impose substantial risks, uncertainties, and burdens on study participants. Interventions under consideration include bone marrow transplantation, antineoplastic or immunomodulatory drugs, ART interruptions, invasive tissue sampling, and other interventions that carry either high risk, or wholly unknown risk, often firstly performed on HIV-infected patients. As ART has become more effective, safer and more convenient, the overall prospect of medical harm from participation in such early-phase studies could exceed any prospect of direct medical benefit. Is it ethical to ask patients to participate in such studies?

Description {#jve2_52-sec-0002}
===========

A wide spectrum of ethical solutions are conceivable to the benefit/risk ratio challenge. Some were drawn from review of solutions to similar challenges in other areas of clinical research (e.g. Phase I cancer studies; various First-in-Human studies). Others use recent insights in several areas of practical ethics to suggest new candidate ethical solutions. The talk maps and comments on these many candidate solutions.

Lessons learned {#jve2_52-sec-0003}
===============

The candidate solutions reviewed fall into four categories: ones that seek to reduce risks in early-phase cure and remission studies; ones that enhance the medical or nonmedical benefits for these studies' participants (or show that those were adequate in the first place), ones that focus on participants' free and informed consent to participate, and ones that emphasize the large benefits to nonparticipating patients.

Conclusions/Next steps {#jve2_52-sec-0004}
======================

The benefit/risk ratio challenge in some early-phase HIV cure and long-term remission studies is serious enough that HIV investigators and oversight bodies should consider a wide range of candidate solutions. Ethicists should help determine which solutions makes ethical sense. Empirical investigators should check their acceptability to a variety of stakeholders.

Social and Behavioural Concepts and Theories

53 Perceptions of HIV remission ("cure") trials and trial intentions among potential participants treated in acute HIV infection
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Background {#jve2_53-sec-0001}
==========

A series of HIV remission trials are being conducted in the Thai Red Cross AIDS Research Centre. Prior to trial invitation, we surveyed eligible, acute HIV individuals on ART in the SEARCH cohort, exploring trial interest, perceived benefits and risks, and factors associated with intentions to participate.

Methods {#jve2_53-sec-0002}
=======

A paper survey was provided in-clinic. Data collection is ongoing; results from Nov-Dec 2015 are presented. Analysis includes descriptive statistics and backwards elimination regression.

Results {#jve2_53-sec-0003}
=======

Among 165 participants the large majority (97%) are male. 139 (84.2%) were somewhat/very interested in learning about HIV remission trials. On open-ended questioning about key factors in decision making, those somewhat/very interested most often referenced anticipated personal and altruistic benefits; those less interested most often referenced risks of harm and personal benefit. Most (n=148, 89.7%) reported that trial decision-making would be theirs alone. For personal benefit, more than half endorsed "a big chance" (n=60, 36.4%) or "definitely would benefit" (n=45, 27.3%). For risk, 59 (36.0%) chose "no chance" or "small chance of harm" and 96 (58.5%) chose "about a 50/50 chance." Most (n=118, 72.4%) chose "a big chance" or "definite" for scientific benefit. Factors associated with intentions to participate in a trial that includes stopping ART (n=96, 58.9% somewhat/very likely) were higher perceptions of scientific benefit (beta=.27, p\<.001) and higher personality trait optimism (beta=.26, p\<.001), R^2^=.16 (F (2, 159)=15.58, p\<.01). Factors associated with intent to participate in a trial with an experimental drug and stopping ART (n=110, 68.3% somewhat/very likely) were higher perceptions of scientific benefit (beta=.35, p\<.001) and lower perceived impact of HIV (beta=−.07, p=.03), R^2^=.16 (F (2, 157)=14.37, p\<.01).

Conclusions {#jve2_53-sec-0004}
===========

This cohort indicated high interest and intention to participate. Though they anticipate personal benefits and frequently described these factors as important to their decisions, the common factor associated with stated intentions was anticipated scientific benefit. Risks were less described, which may reflect uncertainty about types and magnitude of risks, and optimistic bias. The results suggest that informed consent should target the potential for and uncertainty about risks and how the trial design maximizes scientific benefit.

Social and Behavioural Concepts and Theories

54 How curing HIV could influence stigma: a qualitative analysis of men who have sex with men in Guangzhou, China
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Background {#jve2_54-sec-0001}
==========

Stigma associated with men who have sex with men (MSM) living with HIV is heavily entrenched in China, in part due to their status as HIV-infected and in part because of their MSM identity. The purpose of this research was to examine the perceptions of MSM living with HIV on HIV cure research and its potential impact on existing and future stigma.

Methods {#jve2_54-sec-0002}
=======

From June to December 2015, we conducted in-depth interviews with MSM living with HIV. Men living with HIV were recruited at two settings: a local MSM community based organization and the local infectious disease hospital. The interviews were audio-recorded, transcribed (verbatim) and translated into English for analysis. A code based methodology was used to identify themes and structure the analysis.

Results {#jve2_54-sec-0003}
=======

We interviewed 26 individuals and the following themes stood out. First, men stated that an HIV cure could normalize the disease, reduce fear of HIV and HIV infected individuals, and remove stigma that currently serves as a barrier to social engagement for PLWHIV exemplified by these men\'s reluctance to date, marry, or even share a meal with friends and family due to fear of stigmatization. Second, men stated that an HIV cure would remove the feelings of being a perennial patient and reduce the feelings of otherness associated with routines of daily medication and regular hospital visits. Third, men stated that an HIV cure would likely have a limited impact on MSM-related stigma, stating that these views were linked to stereotypes of promiscuity and high rates of STDs in the MSM community and would persist even after a cure.

Conclusions {#jve2_54-sec-0004}
===========

Our data suggest that the development of an HIV cure might influence how HIV is perceived among MSM and related notions of stigma. Empirical research on HIV stigma among HIV cure research participants would be useful to better understand how cure changes HIV-related identities.

Community Engagement in Research and Research Dissemination

55 'I can coexist with HIV': a qualitative study of perceptions of HIV "cure" among people living with HIV in Guangzhou, China

Ma

Q.

1

2

Wu

F.

2

Henderson

G.

3

Rennie

S.

3

Rich

Z.

2

Cheng

Y.

4

Hu

F.

5

Cai

W.

5

Tucker

J.

1

2

University of North Carolina at Chapel Hill

,

Institute for Global Health and Infectious Diseases

,

Chapel Hill

,

United States

,

UNC Project-China

,

Guangzhou

,

China

,

University of North Carolina at Chapel Hill

,

Department of Social Medicine

,

Chapel Hill

,

United States

,

Sun Yat-sen University

,

School for Sociology and Anthropology

,

Guangzhou

,

China

,

Guangzhou Eighth People\'s Hospital

,

Guangzhou

,

China

Background {#jve2_55-sec-0001}
==========

Understanding perceptions and expectations for HIV "cure" by people living with HIV (PLHIV) has become increasingly important for the scientific community in terms of patient recruitment for clinical trials and participant education. The primary goal of this study was to explore the perceptions of HIV cure by PLHIV in China in relation to their views on HIV treatment, stigma, and social identity.

Methods {#jve2_55-sec-0002}
=======

From September 2014 to June 2015, we conducted in-depth interviews with 22 PLHIV in Guangzhou, China. Participants were recruited from the HIV clinic of the largest infectious diseases hospital in south China. Audio-recorded interviews were transcribed verbatim from Mandarin Chinese. A code-based methodology was used to identify themes and structure the analysis.

Results {#jve2_55-sec-0003}
=======

Our qualitative data were categorized into three major themes: 1) Pictures of HIV cure. Our data demonstrated that while they can imagine life without HIV, PLHIV generally thought HIV cure was far away from them, and were realistic about the continuation of their current treatment. 2) Possibility of HIV cure. Ideas about the possibility of HIV cure by PLHIV ranged from optimism to skepticism to pessimism. 3) Life without HIV cure. Some participants had normalized HIV infection and ART adherence in their daily life and adjusted well to the chronic condition of HIV. They emphasized the importance of a positive attitude towards coexisting with HIV. The data also suggested that some participants regarded stigma and discrimination associated with HIV as the biggest concerns in their lives.

Conclusions {#jve2_55-sec-0004}
===========

Our findings indicate that although some PLHIV interviewed in Guangzhou, China, looked forward to changes that HIV cure might bring to their lives, most had little interest in HIV cure. Rather, they preferred to have better ART medication and more education for the general public to eliminate stigma associated with HIV.
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Background {#jve2_56-sec-0001}
==========

"Implementation ethics" was coined in 2006 in the context of AIDS treatment program implementation in Africa. The expression refers to ethical issues raised by implementing a program or an intervention. We discuss whether the concept of implementation ethics applies to HIV cure-related research.

Methods {#jve2_56-sec-0002}
=======

We completed 36 extensive qualitative key informant interviews with a variety of stakeholders in the United States in 2015, including people living with HIV, biomedical and social scientists, bioethicists, members of IRBs and regulators to assess how HIV cure research could be implemented ethically. We hereby summarize overarching questions, topics and priorities raised.

Results {#jve2_56-sec-0003}
=======

Key informants focused their discussions around the requirements of research ethics, study design issues -- including sample size ethics, measurements, safety considerations and risk mitigation strategies, endpoint issues, informed consent, confidentiality and logistical issues affecting implementation of HIV cure studies. Careful treatment of participants, communication, community input and fair representation of participants were identified as paramount for ethical implementation. Respondents provided recommendations for ethical implementation of HIV cure studies, including considerations for the selection of participants, informed consent that fully addresses potential risks and conveys no expectation of individual benefit, adequate scientific justification, use of lowest product doses and shortest study duration, stopping rules for safety-related issues and futility rules for efficacy endpoints, and mechanisms for long-term follow-up of participants given investigational products that may have long-term genotoxic, mutagenic and/or carcinogenic effects. Respondents highlighted considerations for the ethical implementation of HIV cure-related research in resource-limited settings and the need to appreciate HIV prevention and treatment efforts in the context of cure research. An overarching theme was the imperative to appreciate the incremental nature of research and to define criteria for intermediate success when most experiments will not be curative.

Conclusions {#jve2_56-sec-0004}
===========

The field of bioethics should keep pace with the growing number of HIV cure-related clinical studies conducted worldwide. The discourse around the ethical implementation of HIV cure research will require further input from a variety of sources, including scientists, bioethicists and people living with HIV to safeguard the ethics of HIV cure research agenda and resolve implementation ethics challenges as they arise.
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Background {#jve2_57-sec-0001}
==========

In 2015, there were over 100 HIV Cure-related trials operating worldwide. Participation in current, and future, trials may pose health risks for people living with HIV (PLHIV), while being unlikely to deliver therapeutic benefit. As such, there is an ethical imperative for researchers to understand the motivations, expectations and understandings of potential trial participants. This paper reports on a survey of Australian PLHIV which aimed to identify: •familiarity with HIV Cure research and optimism regarding achieving a cure•anticipated benefits of cure•socio-demographic and health-related characteristics of PLHIV who indicate willingness to participate in HIV Cure trials•factors that moderate willingness to participate in a trial.

Methods {#jve2_57-sec-0002}
=======

Data for this study were derived from a cross-sectional survey of PLHIV in Australia conducted in 2015/2016. There were \~800 responses collected via a self-complete instrument that could be filled-in online or using a 'pen and paper' survey. The study was advertised through HIV organisations, relevant email lists, social media and websites. Analysis involved (1) multivariate hierarchical regression to identify factors associated with greater willingness to participate in trials and (2) non-parametric tests to identify participants' expectations regarding HIV cure.

Results {#jve2_57-sec-0003}
=======

Preliminary data analysis shows that not passing HIV to others and not being at risk of ill-health were the most desirable 'HIV Cure' outcomes reported. Approximately 80% indicated willingness to participate in a trial. However, this was reduced if respondents thought participation could result in greater unpredictability of viral load, increased risk of resistance to current antiretroviral treatment, or increased susceptibility to illness. Belief that an HIV Cure would be achieved within the respondent\'s lifetime was associated with greater willingness to participate in a trial.

Conclusions {#jve2_57-sec-0004}
===========

These findings suggest that many Australian PLHIV are open to participating in HIV Cure trials. However, concern about possible effects on treatment efficacy and viral suppression clearly influences willingness, pointing to the importance of high quality informed consent processes. Optimism for achieving an HIV Cure may also influence willingness to participate. This is a further ethical concern as unrealistic optimism may be associated with misunderstanding of the therapeutic benefits of trial participation.
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Background {#jve2_58-sec-0001}
==========

South Africa\'s journey with HIV has seen significant progress, but with 400,000 new infections annually and 3.4 million PLHIV on treatment, our treatment and prevention campaigns are not enough. To end the HIV epidemic a cure is needed. Globally a search for a cure has begun and with its strong history in HIV research and high prevalence rates, South Africa is likely to be involved in cure research. Formative research with 15 stakeholders at an HIV clinic in the Western Cape revealed general awareness and knowledge of HIV cure research to be suboptimal. As the scientific approaches to a cure advance, there is a need for early and sustained engagement with the community to address any misconceptions as well as introducing "cure speak" into the community.

Description {#jve2_58-sec-0002}
===========

To introduce the cure discourse to people living with HIV in South Africa, the Centre for Medical Ethics and Law developed a 14 minute educational video to be shown to patients in waiting rooms at HIV clinics throughout South Africa. It reiterates the well-known messages of treatment and prevention, and introduces cure research. The actors are healthcare workers in an HIV clinic, comedian and doctor Riaad Moosa as well as activists Archbishop Emeritus Desmond Tutu and Zackie Achmat.

Lessons learned {#jve2_58-sec-0003}
===============

Developing such a video is fraught with many challenges, particularly when the science is still quite uncertain. Decisions as to the messages to include will inevitably result in the exclusion of key information, thus careful consideration of the implications of the text is imperative. In particular, the script must not mislead, raise undue or false hope, but inform the community with balanced information. Of importance in this process is the inclusion of the community in the preproduction and postproduction stages. Not only the video itself, but the process must also be seen as an important part of community engagement.

Conclusions/Next steps {#jve2_58-sec-0004}
======================

Educating the community about cure research is challenging. However through a wide engagement with stakeholders and community members, it is possible to develop an educational intervention. It is hoped that this video will encourage others involved with cure research to begin developing their community engagement strategies.

Ethical Aspects and Standards, Including with Respect to Research, Clinical Services, Public Health Policy and Programmes, and Professional Conduct
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Background {#jve2_59-sec-0001}
==========

Intense activity is being directed at strategies for remission or eradication of HIV infection. However, current laboratory assays for HIV reservoir measurement are insufficient to demonstrate clearance of HIV and the best available test is to interrupt antiretroviral therapy (ART) -- known as analytic treatment interruption (ATI) -- for a defined period of time or until viral rebound occurs. Although ATIs are currently used in some HIV cure research, they raise important scientific and ethical questions.

Methods {#jve2_59-sec-0002}
=======

A multidisciplinary group conducted an ethical analysis of the use of ATI in HIV cure research. The analysis examined the rationale for ATI and its potential scientific utility as well as the risks and burdens to study participants. Criteria for use of ATI in HIV cure studies were developed.

Results {#jve2_59-sec-0003}
=======

Despite the ethical obligation to minimize research risks, there are limited data to directly inform risk assessment for ATIs in HIV cure trials. Experts have extrapolated from information from trials using longer repeated treatment interruptions, and from biological assays measuring effects of viral replication and inflammation. Despite these best efforts, it is difficult to ascertain the probability and magnitude of harm from a single ATI. There is also disagreement about the scientific utility of ATI in different types of studies. In spite of these uncertainties, studies involving ATIs must meet three basic ethical criteria: 1)a strong scientific justification for the ATI;2)minimization of risks to study participants; and3)a robust informed consent process.

Conclusions {#jve2_59-sec-0004}
===========

Based on the ethical criteria identified in this analysis, investigators should carefully consider the acceptability of ATIs by providing a strong justification of an ATI and carefully select participants. Further work should be undertaken by clinical researchers in partnership with social scientists, behavioral researchers and ethicists to enhance the ethical conduct of studies employing ATIs.
